Wellness Center USA (WCUI) 10-K 28 Jan 20 2019 FY Annual report Financial data

Document and Entity Information

Document and Entity Information	12 Months Ended
	Sep. 30, 2019USD ($)shares
Document And Entity Information
Entity Registrant Name	Wellness Center USA, Inc.
Entity Central Index Key	0001516887
Document Type	10-K
Document Period End Date	Sep. 30, 2019
Amendment Flag	false
Current Fiscal Year End Date	--09-30
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filer	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float | $	$ 2,773,921
Entity Common Stock, Shares Outstanding | shares	107,497,077
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2019

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Sep. 30, 2019	Sep. 30, 2018
Current Assets
Cash	$ 53,147	$ 4,210
Prepaid expenses and other current assets	55,000	1,550
Total Current Assets	108,147	5,760
Property and equipment, net	1,562	2,619
Other assets		16,760
Total Other Assets	1,562	19,379
TOTAL ASSETS	109,709	25,139
Current Liabilities
Accounts payable and accrued expenses	794,453	572,753
Deferred revenue		8,624
Convertible notes payable		202,922
Loans payable from officers and shareholders	399,250	66,000
Total Current Liabilities	1,193,703	850,299
Shareholders' Deficit
Common stock, par value $0.001, 200,000,000 shares authorized; 107,497,077 and 100,952,569 shares issued and outstanding, respectively	107,497	100,952
Additional paid-in capital	23,777,647	22,450,252
Accumulated deficit	(25,362,287)	(22,974,740)
Total Wellness Center USA shareholders' deficit	(1,477,143)	(423,536)
Non-controlling interest	393,149	(401,624)
Total Shareholder's deficit	(1,083,994)	(825,160)
TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT	$ 109,709	$ 25,139

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2017
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000	185,000,000
Common stock, shares, issued	107,497,077	100,952,569	90,284,916
Common stock, shares, outstanding	107,497,077	100,952,569	90,284,916

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Sales:
Total Sales	$ 33,375	$ 213,723
Cost of goods sold	20,025	79,960
Gross profit	13,350	133,763
Operating expenses	1,779,934	2,226,362
Loss from operations	(1,766,584)	(2,092,599)
Other expenses
Amortization of debt discount	(72,078)	(318,038)
Financing costs	(182,064)	(891,583)
Loss on modification of conversion price on convertible note payable		(158,400)
Loss on modification of exercise price on warrants in connection with convertible note payable		(5,445)
Interest expense	(25,298)	(27,354)
Total other expenses	(279,440)	(1,400,820)
NET LOSS	(2,046,024)	(3,493,419)
Net loss attributable to non-controlling interest	63,860	84,236
Loss from deconsolidation of non-controlling interest	(405,383)
NET LOSS ATTRIBUTABLE TO WELLNESS CENTER USA, INC.	(2,387,547)	(3,409,183)
Deemed dividend relating to settlement with shareholder		(433,000)
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS	$ (2,387,547)	$ (3,842,183)
BASIC AND DILUTED LOSS PER SHARE	$ (0.02)	$ (0.04)
WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING BASIC AND DILUTED	105,421,218	94,475,383
Trade [Member]
Sales:
Total Sales	$ 19,508	$ 140,023
Consulting Services [Member]
Sales:
Total Sales	$ 13,867	$ 73,700

Consolidated Statements of Shar

Consolidated Statements of Shareholders' Deficit - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Total WCUI Deficit [Member]	Non-controlling Interest [Member]	Total
Balance at Sep. 30, 2017	$ 90,285	$ 19,069,211	$ (19,132,557)	$ 26,939	$ (317,388)	$ (290,449)
Balance, shares at Sep. 30, 2017	90,284,916
Common shares issued for cash	$ 1,614	175,386		177,000		177,000
Common shares issued for cash, shares	1,614,286
Exercise of stock warrants	$ 1,407	169,507		170,914		$ 170,914
Exercise of stock warrants, shares	1,407,619
Fair value of common stock issued for services	$ 770	110,530		111,300		$ 111,300
Fair value of common stock issued for services, shares	770,000
Shares issued upon conversion of note payable and accrued interest	$ 1,746	172,817		174,563		174,563
Shares issued upon conversion of note payable and accrued interest, shares	1,745,631
Shares issued upon conversion of loans payable from officers and shareholders	$ 2,801	404,199		407,000		407,000
Shares issued upon conversion of loans payable from officers and shareholders, shares	2,800,713
Fair value of additional shares issued upon conversion of loans payable from officers and shareholders	$ 218	30,365		30,583		30,583
Fair value of additional shares issued upon conversion of loans payable from officers and shareholders, shares	218,452
Fair value of warrants issued as an inducement for conversion of loans payable from officers and shareholders		689,934		689,934		689,934
Fair value of vested stock options		612,503		612,503		612,503
Fair value of common stock issued in connection with convertible note payable	$ 748	113,591		114,339		114,339
Fair value of common stock issued in connection with convertible note payable, shares	747,751
Fair value of shares and warrants issued upon settlement of Favored Nations clause	$ 1,067	431,933	(433,000)
Fair value of shares and warrants issued upon settlement of Favored Nations clause, shares	1,066,667
Fair value of shares and warrants issued to a stockholder upon settlement	$ 296	56,431		56,727		56,727
Fair value of shares and warrants issued to a stockholder upon settlement, shares	296,534
Discount on convertible note payable due to beneficial conversion and warrants		250,000		250,000		250,000
Loss on modification of conversion price and exercise price on warrants in connection with convertible note payable		163,845		163,845		163,845
Fair value of additional shares issued to induce conversions of note payable
Termination of non-controlling interest agreement
Net loss			(3,409,183)	(3,409,183)	(84,236)	(3,493,419)
Balance at Sep. 30, 2018	$ 100,952	22,450,252	(22,974,740)	(423,536)	(401,624)	(825,160)
Balance, shares at Sep. 30, 2018	100,952,569
Common shares issued for cash	$ 143	9,857		10,000		$ 10,000
Common shares issued for cash, shares	142,857
Exercise of stock warrants, shares
Fair value of common stock issued for services	$ 1,277	77,752		79,029		$ 79,029
Fair value of common stock issued for services, shares	1,277,143
Shares issued upon conversion of note payable and accrued interest	$ 4,811	285,361		290,172		290,172
Shares issued upon conversion of note payable and accrued interest, shares	4,810,222
Fair value of vested stock options		300,925		300,925		300,925
Fair value of common stock issued in connection with convertible note payable	$ 314	21,686		22,000		22,000
Fair value of common stock issued in connection with convertible note payable, shares	314,286
Fair value of additional shares issued to induce conversions of note payable		160,064		160,064		160,064
Termination of non-controlling interest agreement			(405,383)	(405,383)	405,383	(405,383)
Contribution of capital by joint venture partner		471,750		471,750	453,250	925,000
Net loss			(1,982,164)	(1,982,164)	(63,860)	(2,046,024)
Balance at Sep. 30, 2019	$ 107,497	$ 23,777,647	$ (25,362,287)	$ (1,477,143)	$ 393,149	$ (1,083,994)
Balance, shares at Sep. 30, 2019	107,497,077

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Cash Flows from Operating Activities
Net loss	$ (2,046,024)	$ (3,493,419)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	1,057	2,507
Amortization of debt discount	72,078	318,038
Fair value of common shares issued for services	79,029	111,300
Fair value of stock options issued for services	300,925	612,503
Fair value of additional shares issued upon conversion of loans payable from officers and shareholders		30,583
Fair value of warrants issued upon conversion of loans payable from officers and shareholders		689,934
Fair value of additional shares issued to induce conversions of note payable	160,064
Fair value of common stock issued with convertible note payable	22,000	114,339
Loss on abandonment of lease	65,000
Loss on modification of conversion price on convertible note payable		158,400
Loss on modification of exercise price on warrants in connection with convertible note payable		5,445
Fair value of additional shares and warrants issued to a stockholder		56,727
(Increase) Decrease in:
Accounts receivable		24,999
Inventories		12,335
Prepaid expenses and other assets	(36,690)	201
(Decrease) Increase in:
Accounts payable and accrued expenses	171,872	378,948
Accrued payroll - officers		(13,440)
Deferred revenue	(8,624)	(46,473)
Net cash used in operating activities	(1,219,313)	(1,037,073)
Cash Flows from Financing Activities
Proceeds from loans payable from officers and shareholders	358,250	434,500
Repayment of loans payable from officers and shareholders	(25,000)	(20,500)
Proceeds from convertible note payable		250,000
Common stock and warrants issued for cash	10,000	177,000
Exercise of stock warrants		170,914
Contribution of capital by joint venture partner	925,000
Net cash provided by financing activities	1,268,250	1,011,914
Net increase (decrease) in cash	48,937	(25,159)
Cash beginning of year	4,210	29,369
Cash end of year	53,147	4,210
Supplemental cash flows disclosures:
Interest paid
Taxes paid
Supplemental non-cash financing disclosures:
Debt discount on issuance of convertible note payable		250,000
Conversion of convertible note payable and accrued interest into common shares	290,172	184,126
Conversion of loans payable from officers and shareholders into common shares		$ 407,000

Basis of Presentation

Basis of Presentation	12 Months Ended
	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	NOTE 1 – BASIS OF PRESENTATION Organization and Operations Wellness Center USA, Inc. (“WCUI” or the “Company”) was incorporated in June 2010 under the laws of the State of Nevada. The Company initially engaged in online sports and nutrition supplements marketing and distribution. The Company subsequently expanded into additional businesses within the healthcare and medical sectors through acquisitions, including Psoria-Shield Inc. (“PSI”), National Pain Centers, Inc. (“NPC”), and StealthCo Inc. (“SCI”), d/b/a Stealth Mark, Inc. The Company currently operates in the following business segments: (i) distribution of targeted Ultra Violet (“UV”) phototherapy devices for dermatology; and (ii) authentication and encryption products and services. The segments are operated, respectively, through PSI and SCI. Going Concern The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying consolidated financial statements, the Company has not yet generated significant revenues and has incurred recurring net losses. During the year ended September 30, 2019, the Company incurred a net loss of $2,046,024 and used cash in operations of $1,219,313, and had a shareholders’ deficit of $1,083,994 as of September 30, 2019. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to raise additional funds and implement its strategies. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. At September 30, 2019, the Company had cash on hand in the amount of $53,147. Management estimates it has sufficient cash to operate through February 2020. The ability to continue as a going concern is dependent on the Company attaining and maintaining profitable operations in the future and raising additional capital soon to meet its obligations and repay its liabilities arising from normal business operations when they come due. Since inception, we have funded our operations primarily through equity and debt financings and we expect to continue to rely on these sources of capital in the future. During the year ended September 30, 2019, the Company received $1,293,250 through loans payable from officers and shareholders, the sale of its common stock, and from contributions of capital by a joint venture partner. Subsequent to September 30, 2019, the Company received additional advances from shareholders of $310,000 (see Note 13). No assurance can be given that any future financing will be available or, if available, that it will be on terms that are satisfactory to the Company. Even if the Company is able to obtain additional financing, it may contain undue restrictions on our operations, in the case of debt financing, or cause substantial dilution for our stock holders, in case of equity financing.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Consolidation The Company’s consolidated subsidiaries and/or entities are as follows: Name of consolidated subsidiary or entity State or other jurisdiction of incorporation or organization Date of incorporation or formation (date of acquisition/disposition, if applicable) Attributable interest Psoria-Shield Inc. (“PSI”) The State of Florida June 17, 2009 100 % StealthCo, Inc. (“StealthCo”) The State of Illinois March 18, 2014 100 % Psoria Development Company LLC. (“PDC”) The State of Illinois January 15, 2015 50 % NEO Phototherapy LLC (“NEO”) The State of Illinois December 2018 50.5 % Use of Estimates The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the financial statement date, and reported amounts of revenue and expenses during the reporting period. Significant estimates are used in the valuation of accounts receivable and allowance for uncollectible amounts, inventory and obsolescence reserves, accruals for potential liabilities, valuations of stock-based compensation, realization of deferred tax assets, among others. Actual results could differ from these estimates. Income (Loss) Per Share Basic loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of outstanding common shares during the period. Diluted loss per share is computed by dividing the net loss applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued. For the years ended September 30, 2019 and 2018, the basic and diluted shares outstanding were the same, as potentially dilutive shares were considered anti-dilutive. At September 30, 2019 and 2018, the dilutive impact of outstanding stock options of 15,237,738 and 17,946,667 shares, respectively, and outstanding warrants for 66,484,049 and 67,907,728 shares, respectively, have been excluded because their impact on the loss per share is anti-dilutive. Revenue Recognition In May 2014, the FASB issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (Topic 606). For trade sales, the Company generates its revenue from sales contracts with customers with revenues being generated upon the shipment of merchandise, or for c We sell our products through two main sales channels: 1) directly to customers who use our products (the “Direct Channel”) and 2) to distribution partners who resell our products (the “Indirect Channel”). Under the Direct Channel, we sell our products to and we receive payment directly from customers who purchase our products. Under our Indirect Channel, we have entered into distribution agreements that allow the distributors to sell our products and fulfill performance obligations under the agreements. We determine revenue recognition through the following steps: ● Identification of the contract, or contracts, with a customer ● Identification of the performance obligations in the contract ● Determination of the transaction price ● Allocation of the transaction price to the performance obligations in the contract ● Recognition of revenue when, or as, we satisfy a performance obligation. Revenue is generally recognized upon shipment or when a service has been completed, unless we have significant performance obligations for services still to be completed. We recognize revenue when a material reversal is no longer probable. Payments received before the relevant criteria for revenue recognition are satisfied are recorded as deferred revenue. Deferred revenue at September 30, 2018 was $8,624. There was no deferred revenue at September 30, 2019. Property and Equipment Property and equipment are carried at cost less accumulated depreciation and amortization. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. The Company has determined the estimated useful lives of its property and equipment, as follows: Computer equipment 5 years Medical equipment 5 years Furniture and fixtures 7 years Vehicles 3 years Software 3 years Maintenance and repairs are charged to expense as incurred. The cost and accumulated depreciation of assets sold or otherwise disposed of are removed from the related accounts and the resulting gain or loss is reflected in the statements of operations. Management assesses the carrying value of property and equipment whenever events or changes in circumstances indicate that the carrying value may not be recoverable. If there is indication of impairment, management prepares an estimate of future cash flows expected to result from the use of the asset and its eventual disposition. If these cash flows are less than the carrying amount of the asset, an impairment loss is recognized to write down the asset to its estimated fair value. Income Taxes Income tax expense is based on pretax financial accounting income. Deferred tax assets and liabilities are recognized for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts. Valuation allowances are recorded to reduce deferred tax assets to the amount that will more likely than not be realized. The Company recorded a valuation allowance against its deferred tax assets as of September 30, 2019 and 2018. The Company accounts for uncertainty in income taxes using a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50 percent likely of being realized upon settlement. The Company classifies the liability for unrecognized tax benefits as current to the extent that the Company anticipates payment (or receipt) of cash within one year. Interest and penalties related to uncertain tax positions are recognized in the provision for income taxes. Fair Value measurements The Company determines the fair value of its assets and liabilities based on the exchange price in U.S. dollars that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The Company uses a fair value hierarchy with three levels of inputs, of which the first two are considered observable and the last unobservable, to measure fair value: ● Level 1 — ● Level 2 — ● Level 3 — The carrying amounts of financial instruments such as cash, and accounts payable and accrued liabilities, approximate the related fair values due to the short-term maturities of these instruments. Non-controlling Interest Through November 2018, non-controlling interest represented the non-controlling interest holder’s proportionate share of the equity of the Company’s majority-owned subsidiary, PDC. Non-controlling interest is adjusted for the non-controlling interest holder’s proportionate share of the earnings or losses and other comprehensive income (loss), if any, and the non-controlling interest continues to be attributed its share of losses even if that attribution results in a deficit non-controlling interest balance. On November 15, 2018, PSI and TMA entered into a Withdraw and Mutual Release Agreement to terminate their joint venture agreement. On the date of termination, the non-controlling interest’s share of the accumulated losses of the joint venture totaled to $405,383. Upon termination, during the three months ended December 31, 2018, the Company wrote-off the non-controlling interest’s share of the accumulated losses and recorded a loss from the deconsolidation of a non-controlling interest of $405,383. In December 2018, PSI entered into a Joint Venture Agreement with GEN2 to further development, marketing, licensing and/or sale of PSI technology and products. Pursuant to the Joint Venture Agreement, the venture will be conducted through NEO. PSI and GEN2 will be the members of NEO, owning 50.5% and 36.0%, respectively, of the Units issued in connection with the organization of NEO. An additional 13.5% of such Units will be reserved for issuance as incentives for key employees and consultants. Until such shares are distributed, the Company controls 68% of the joint venture and GEN2 the remaining 32%. PSI and GEN2 will manage NEO’s day-to-day operations. PSI will contribute PSI technology to NEO and GEN2 will contribute $700,000. As of September 30, 2019, NEO’s operations required additional funding above the $700,000 documented in the agreement, and as of September 30, 2019, GEN2 had received $925,000 of investments to contribute to NEO. As of September 30, 2019, the Company controlled 51% of the joint venture, GEN2 controlled 39% and another individual controlled the remaining 10%. The Company recorded its proportionate share of the contributions received of $471,750 to additional paid-in-capital and $453,250 to non-controlling interest as of that date. During the year ended September 30, 2019, NEO recorded a loss of $122,655 relating to its operations. Repayment of the investment by GEN2 will begin through and upon the date which NEO has realized and retained cumulative net income/distributable cash in the amount of $300,000. Distributions thereafter will be made to PSI, GEN2 and other members in proportion to their respective Unit ownership, at the times and in the manner determined from time to time by the managers, in their sole discretion. GEN2 consists of accredited investors, and investment participation of $700,000 from several WCUI officers and directors, including Calvin R. O’Harrow and Roy M. Harsch. Stock-Based Compensation The Company periodically grants stock options and warrants to employees and non-employees in non-capital raising transactions as compensation for services rendered. The Company accounts for stock option and stock warrant grants to employees based on the authoritative guidance provided by the Financial Accounting Standards Board where the value of the award is measured on the date of grant and recognized over the vesting period. The Company accounts for stock option and stock warrant grants to non-employees in accordance with the authoritative guidance of the Financial Accounting Standards Board where the value of the stock compensation is determined based upon the measurement date at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Non-employee stock-based compensation charges generally are amortized over the vesting period on a straight-line basis. In certain circumstances where there are no future performance requirements by the non-employee, option or warrant grants are immediately vested and the total stock-based compensation charge is recorded in the period of the measurement date. The fair value of the Company’s common stock option and warrant grants are estimated using a Black-Scholes Merton option pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the common stock options, estimated forfeitures and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes option pricing model, and based on actual experience. The assumptions used in the Black-Scholes Merton option pricing model could materially affect compensation expense recorded in future periods. Recently Issued Accounting Pronouncements In February 2016, the FASB issued Accounting Standards Update (ASU) No. 2016-02, Leases. ASU 2016-02 requires a lessee to record a right of use asset and a corresponding lease liability on the balance sheet for all leases with terms longer than 12 months. ASU 2016-02 is effective for all interim and annual reporting periods beginning after December 15, 2018. Early adoption is permitted. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is in the process of evaluating the impact of ASU 2016-02 on the Company’s financial statements and disclosures. In June 2018, the FASB issued ASU No. 2018-07, “Compensation - Stock Compensation (Topic 718); Improvements to Non-Employee Share-Based Payment Accounting” (“ASU 2018-07”). ASU 2018-07 generally aligns the measurement and classification of share-based awards to non-employees with that of share-based awards to employees. Non-employee equity awards will be measured at the fair value of the equity instruments to be issued, as of the grant date, and the resulting amount will be recognized as expense over the expected or contractual term of the award. The ASU applies to all share-based payments to nonemployees in exchange for goods or services used or consumed in an entity’s own operations. It does not apply to instruments issued to a lender or investor in a financing transaction, or to instruments granted when selling goods or services to customers. ASU 2018-07 is effective for annual periods beginning after December 15, 2018, and interim periods within those annual periods. Early adoption is permitted. The Company is currently evaluating the expected impact that the standard could have on its financial statements and related disclosures. Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

Property and Equipment

Property and Equipment	12 Months Ended
	Sep. 30, 2019
Property, Plant and Equipment [Abstract]
Property and Equipment	NOTE 3 - PROPERTY AND EQUIPMENT Property and equipment consisted of the following at September 30, 2019 and 2018: September 30, 2019 September 30, 2018 Vehicles $ 15,000 $ 15,000 Computer equipment 10,456 10,456 Furniture and fixtures 23,998 23,998 Medical equipment 18,889 18,889 Software 23,207 23,207 Leasehold improvements 15,170 15,170 106,720 106,720 Less: accumulated depreciation and amortization (105,158 ) (104,101 ) Property and equipment, net $ 1,562 $ 2,619 Depreciation expense for the years ended September 30, 2019 and 2018 was $1,057 and $2,507, respectively.

Loans Payable from Officers and

Loans Payable from Officers and Shareholders	12 Months Ended
	Sep. 30, 2019
Debt Disclosure [Abstract]
Loans Payable from Officers and Shareholders	NOTE 4 – LOANS PAYABLE FROM OFFICERS AND SHAREHOLDERS As of September 30, 2017, loans payable to shareholders of $59,000 were outstanding. During the year ended September 30, 2018, the Company borrowed $434,500 under 22 short-term, unsecured loans. The loans have an interest rate of eight percent and are due one year from the date of issuance. During the year ended September 30, 2018, the Company repaid $20,500 of the loans payable and $407,000 were converted into 2,800,713 shares of the Company’s common stock. In connection with the conversion of the loans payable, the Company issued warrants to purchase 6,038,336 shares of common stock to the holders as an inducement to convert. The warrants expire five years from the date of grant and have exercise prices of $0.14 and $0.18 per share. The fair value of the warrants of $689,934 was recorded as financing costs during the year ended September 30, 2018 and was based on a probability affected Black-Scholes Merton option pricing model with stock prices of $0.13 and $0.14, volatility of 124.60% and 124.73% and risk-free rates of 2.37% and 2.43%. In addition to the warrants, the Company offered certain loan holders, who were not officers or directors, to convert at a rate below the market price of the stock on the date of conversion. An aggregate of 218,452 additional common shares were issued to these loan holders with a value of $30,583 on the date of conversion. The Company recorded the amount as a financing cost during the year ended September 30, 2018. As of September 30, 2018, loans payable from officers and shareholders of $66,000 were outstanding. During the year ended September 30, 2019, the Company borrowed $358,250 from its officers and shareholders and repaid $25,000. All of the loans are unsecured, have an interest rate of eight percent per annum and are due one year from the date of issuance. As of September 30, 2019, loans payable to officers and shareholders of $399,250 were outstanding.

Convertible Note Agreements

Convertible Note Agreements	12 Months Ended
	Sep. 30, 2019
Debt Disclosure [Abstract]
Convertible Note Agreements	NOTE 5 – CONVERTIBLE NOTE AGREEMENTS Convertible notes payable consisted of the following at September 30, 2019 and 2018: September 30, 2019 September 30, 2018 Convertible note payable (a) $ - $ 165,000 Convertible note payable (b) - 110,000 Debt discount – unamortized balance - (72,078 ) Convertible notes payable, net $ - $ 202,922 (a) On March 5, 2018, the Company entered into a Convertible Note Payable Agreement with an individual under which the Company borrowed $165,000. Net proceeds received by the Company under the agreement after payment of a $15,000 fee to the lender was $150,000. In connection with the agreement, the Company issued the individual 300,000 restricted shares of its common stock with a fair value of $48,000 and warrants to purchase 660,000 shares of its common stock, which vested upon grant. The warrants expire five years from the date of grant and have an exercise price of $0.20 per share. The note payable accrues interest at eight percent per annum, is unsecured and is convertible at any time after the 90th day from the issue date into the Company’s common stock at the fixed conversion price of $0.10 per share. The note matured in October 2018. The Company calculated the related fair value of the warrants issued to the noteholder to be $55,032 using a Black Scholes Merton option pricing model and performing a relative value calculation. The Company then made a calculation to determine if a beneficial conversion feature (BCF) existed. The beneficial conversion was based upon the effective conversion price based on the proceeds received that were allocated to the convertible instrument. Based upon the Company’s calculation, it was determined that a beneficial conversion feature existed amounting to $94,968 and was recorded as a debt discount. As such the Company recognized a debt discount at the date of issuance in the aggregate amount of $165,000 relating to the $15,000 fees paid to the lender, the relative value of the warrants and the BCF. The note discount is being amortized over the term of the note and the unamortized portion is recognized as a reduction to the carrying amount of the Convertible note (a valuation debt discount). The balance of the unamortized discount at September 30, 2018 was $3,837. During the year ended September 30, 2019, the Company amended the terms of the agreement by extending the maturity date to January 2019 and reducing the conversion price from $0.10 per share to $0.07 per share. The reduction of the conversion price caused the Company to issue an additional 744,732 shares, which on the dates of amendment had a combined total fair value of $51,434, which was recorded a financing cost during the year ended September 30, 2019. During the year ended September 30, 2019, the individual converted $165,000 of the convertible note payable and $8,783 of accrued interest into 2,482,441 shares of the Company’s common stock. During the year ended September 30, 2019, the Company amortized the remaining $3,837 of debt discount, leaving no unamortized balance at September 30, 2019. No amounts were outstanding under the agreement as of September 30, 2019. (b) On July 11, 2018, the Company entered into another Convertible Note Payable Agreement with the same individual under which the Company borrowed an additional $110,000. Net proceeds received by the Company under the agreement after payment of a $10,000 fee to the lender was $100,000. In connection with the agreement, the Company issued the individual 200,000 restricted shares of its common stock with a fair value of $36,000 and warrants to purchase 440,000 shares of its common stock, which vested upon grant. The warrants expire five years from the date of grant and have an exercise price of $0.18 per share. The note payable accrues interest at eight percent per annum, is unsecured and is convertible at any time after the 90th day from the issue date into the Company’s common stock at the fixed conversion price of $0.15 per share. The note matures in February 2019, but may be extended at the option of the individual. The Company may prepay the note at any time immediately following the issue date upon seven days’ prior written notice. The note was converted into shares of the Company’s common stock (see below). The Company calculated the related fair value of the warrants issued to the noteholder to be $66,440 using a Black Scholes Merton option pricing model and performing a relative value calculation. The Company then made a calculation to determine if a beneficial conversion feature (BCF) existed. The beneficial conversion was based upon the effective conversion price based on the proceeds received that were allocated to the convertible instrument. Based upon the Company’s calculation, it was determined that a beneficial conversion feature existed amounting to $33,560 and was recorded as a debt discount. As such the Company recognized a debt discount at the date of issuance in the aggregate amount of $110,000 relating to the $10,000 fees paid to the lender, the relative value of the warrants and the BCF. The note discount is being amortized over the term of the note and the unamortized portion is recognized as a reduction to the carrying amount of the Convertible note (a valuation debt discount). As of September 30, 2018, the Company had amortized $41,759 of debt discount, leaving an unamortized balance of $68,241 at September 30, 2018. During the year ended September 30, 2019, the Company amended the terms of the agreement by reducing the conversion price from $0.15 per share to $0.05 per share. The reduction of the conversion price caused the Company to issue an additional 1,551,854 shares, which on the date of amendment had a fair value of $108,630, which was recorded a financing cost during the year ended September 30, 2019. During the year ended September 30, 2019, the Company amortized $68,241 of debt discount, leaving no unamortized balance at September 30, 2019. On April 2, 2019, the individual converted the note payable of $110,000 and $6,389 of accrued interest into 2,327,781 shares of the Company’s common stock. No amounts were outstanding under the agreement as of September 30, 2019.

Shareholders' Equity

Shareholders' Equity	12 Months Ended
	Sep. 30, 2019
Equity [Abstract]
Shareholders' Equity	NOTE 6 – SHAREHOLDERS’ EQUITY Authorized shares As of September 30, 2017, the Company was authorized by its Articles of Incorporation to issue up to 185,000,000 shares of common stock, par value $0.001 per share. Holders of shares of common stock have full voting rights, one vote for each share held of record. Shareholders are entitled to receive dividends as may be declared by the Board out of funds legally available therefore and share pro rata in any distributions to shareholders upon liquidation. Shareholders have no conversion, pre-emptive or subscription rights. All outstanding shares of common stock are fully paid and non-assessable. As of September 30, 2018 and 2017, there were 100,952,569 and 90,284,916 shares of common stock issued and outstanding, respectively. On September 3, 2019, the Company’s Board of Directors unanimously approved the amendment of its Articles of Incorporation to increase the total authorized capital stock from 185,000,000 common shares to 200,000,000 common shares. As of September 18, 2019, holders of a majority of the outstanding shares of voting capital stock executed written stockholder consents approving this action and the Company amended its Articles of Incorporation through a filing of a Certificate of Amendment on October 11, 2019. As of September 30, 2019, there were 107,497,077 shares of common stock issued and outstanding. Common shares issued for cash During the year ended September 30, 2018, the Company received $177,000 from the sale of 1,614,286 shares of its common stock. In connection with the sales, the Company issued warrants to the shareholders to purchase 3,228,572 shares of the Company’s common stock. The warrants expire five years from the date of grant and have exercise prices of $0.15 and $0.18 per share. During the year ended September 30, 2019, the Company received $10,000 from the sale of 142,857 shares of its common stock. In connection with the sale, the Company issued a warrant to the shareholder to purchase 284,714 shares of the Company’s common stock. The warrant expires five years from the date of grant and has an exercise price of $0.15 per share. Common shares issued for services During the year ended September 30, 2018, the Company issued 770,000 shares of its common stock valued at $111,300 for services provided by WCUI and PSI consultants. The shares were valued at the trading price of the common stock at the date of issuance and were recorded as compensation expense during the year ended September 30, 2018. During the year ended September 30, 2019, the Company issued 1,277,143 shares of its common stock valued at $79,029 for services provided by WCUI consultants. The shares were valued at the trading price of the common stock at the date of issuance and were recorded as compensation expense during the year ended September 30, 2019. Common Shares Issued in Connection with the Settlement of an Equity Agreement During the year ended September 30, 2017, the Company completed a sale of common stock and warrants with a subscriber whereby the Company sold to the subscriber 1,600,000 shares of common stock and warrants to acquire 1,600,000 shares of common at a price of $0.40 per share, for total purchase consideration of $400,000 ($0.25 per unit). The subscription agreement also included a Favored Nation clause that in the event a subsequent private offering occurs at a price less than $.25 per share that was paid by the subscriber, then the subscriber’s stock unit price shall be proportionately adjusted to the identical ration of 40% discount of the market price in the date of the subscription agreement. Upon issuance of the instrument, no liability for the Favored Nation clause was considered necessary as it was determined that ASC 480-10 did not apply as it is a conditional obligation embedded in a share. During the year ended September 2018, the Company sold 333,333 shares of common stock at $0.15 per share and a warrant to acquire 666,667 shares of common stock at $0.18 per share to an investor that triggered the Favored Nation clause. To avoid the issuance of any future potential shares, the Company and the subscriber entered in an agreement on May 15, 2018, whereby the Company would issue an additional 1,066,667 shares common stock to the subscriber, cancel the previously issued 1,600,000 warrants, and issue a new warrant to acquire 5,334,334 shares of common stock at $.18 per share. To account for the issuance, the Company determined that other than par value, no other value would be ascribed to the additional 1,066,667 shares of common stock that were issued and due under the Favored Nations clause for the reasons detailed above. The Company also determined that it should record the incremental difference of $433,000 between the fair value of the canceled warrant of $185,000 and the fair value of new warrant of $618,000 at the date of the agreement. Given that no services were provided to the Company, the difference in fair value of the warrants before and after the modification was treated as a deemed dividend. Subsequent to the above issuance, the Company and the shareholder entered into a settlement agreement that will eliminate the Favored Nation clause. As such, in November 2018, the Company issued 296,534 shares and a warrant to acquire 770,987 shares of common stock at $0.18 per share. The fair value of the shares issued was $17,792 and the fair value of the warrants was $38,935. As these values were part of a settlement agreement, the total amount of $56,727 was recorded as a financing cost during the year ended September 30, 2018. Stock Options On December 22, 2010, effective retroactively as of June 30, 2010, the Company’s Board of Directors approved the adoption of the “2010 Non-Qualified Stock Option Plan” (“2010 Option Plan”) by unanimous consent. The 2010 Option Plan was initiated to encourage and enable officers, directors, consultants, advisors and key employees of the Company to acquire and retain a proprietary interest in the Company by ownership of its common stock. A total of 7,500,000 of the authorized shares of the Company’s common stock may be subject to, or issued pursuant to, the terms of the plan. Effective January 1, 2018, the Board of Directors approved to increase the number of authorized shares of the Company’s common stock that may be subject to, or issued pursuant to, the terms of the plan from 7,500,000 to 30,000,000. The Company’s policy is to recognize compensation cost for awards with only service conditions and a graded vesting schedule on a straight-line basis over the requisite service period for the entire award. Additionally, the Company’s policy is to issue new shares of common stock to satisfy stock option exercises. The Company applied fair value accounting for all share based payments awards. The fair value of each option granted is estimated on the date of grant using the Black-Scholes option-pricing model. Grants during Fiscal Year Ended September 30, 2018 Options Granted in Accordance with Employment Agreements During the year ended September 30, 2018, the Company entered into employment agreements with four employees of SCI. Under the agreements, the Company issued options to purchase a combined total of 2,800,000 shares of its common stock with a fair value of $396,308. The options are exercisable over a term of five years, with exercise prices ranging from $0.10 to $0.19. The Company valued the options using a Black-Scholes option pricing model. A combined total of 675,000 shares vested in equal amounts over a three-month period, starting on January 1, 2018, with the remainder vesting in equal amounts over the following one year and two months. Further, beginning on January 1, 2018, they will be granted additional stock options to purchase up to an aggregate total of 275,000 shares of the Company’s common stock each quarter. The options are exercisable over a five-year period, are issuable on the last day of each quarter ending and vest immediately on the date of grant. All options accelerate and become fully vested upon the sale or change of control of the Company. During the year ended September 30, 2019 and 2018, the Company recorded $44,275 and $271,804 of stock compensation, respectively, for the value of the options, and as of September 30, 2019, no unvested compensation remained that will be amortized over the remaining vesting period. Other Grants During the year ended September 30, 2018, the Company granted options to purchase 8,517,500 shares of its common stock to its officers, directors and employees with a fair value of $1,004,450. The options have an exercise price of $0.14 per share and expire five years from the date of grant. The shares will vest in various periods. The Company valued the options using a Black-Scholes option pricing model. During the years ended September 30, 2019 and 2018, the Company recorded $256,650 and $340,699 of stock compensation, respectively, for the value of the vested options, and as of September 30, 2019, unvested compensation of $330,333 remained that will be amortized over the remaining vesting period. The assumptions used for options granted during the year ended September 30, 2018 are as follows: Exercise price $ 0.10 - 0.19 Expected dividends - Expected volatility 121.1% - 130.2 % Risk free interest rate 2.01% - 2.85 % Expected life of options 2.5 Grants during Fiscal Year Ended September 30, 2019 During the year ended September 30, 2019, the Company granted options to an employee to purchase an aggregate total of 250,000 shares of its common stock with an aggregate fair value of $10,366. The options have exercise prices ranging from $0.03 to $0.06 per share and expire five years from the date of grant. The shares vested equally each quarter beginning on December 31, 2018. The Company valued the options using a Black-Scholes option pricing model. During the year ended September 30, 2019, the Company recorded $10,366 of stock compensation for the value of the options, and as of September 30, 2019, no unvested compensation remained that will be amortized over the remaining vesting period. The assumptions used for options granted during the year ended September 30, 2019 are as follows: Exercise price $ 0.03 - 0.06 Expected dividends - Expected volatility 126.8% - 144.0 % Risk free interest rate 1.60% - 2.47 % Expected life of options 2.5 The table below summarizes the Company’s stock option activities for the years ended September 30, 2019 and 2018: Number of Exercise Weighted Average Fair Value Balance, September 30, 2017 6,822,500 $ 0.10 – 2.00 $ 0.51 $ 1,865,628 Granted 11,317,500 0.10 – 0.19 0.14 1,379,127 Cancelled (183,333 ) 0.14 0.14 - Exercised - - - - Expired (10,000 ) 0.75 0.75 - Balance, September 30, 2018 17,946,667 $ 0.10 - 2.00 $ 0.28 $ 3,244,755 Granted 250,000 0.03 - 0.06 0.05 10,366 Cancelled (646,429 ) 0.14 – 0.19 0.17 - Exercised - - - - Expired (2,312,500 ) 0.13 – 0.40 0.37 - Balance, September 30, 2019 15,237,738 $ 0.03 – 2.00 $ 0.27 $ 3,255,121 Vested and exercisable, September 30, 2019 12,012,738 $ 0.03 - 2.00 $ 0.30 $ 2,803,621 Unvested, September 30, 2019 3,225,000 $ 0.14 $ 0.14 $ 451,500 There was no aggregate intrinsic value for option shares outstanding at September 30, 2019. The following table summarizes information concerning outstanding and exercisable options as of September 30, 2019: Options Outstanding Options Exercisable Range of Exercise Prices Number Outstanding Average Remaining Contractual Life (in years) Weighted Average Exercise Price Number Exercisable Average Remaining Contractual Weighted Average Exercise Price $ 0.01 - 0.39 13,775,238 3.11 $ 0.15 10,300,238 3.07 $ 0.15 0.40 - 0.99 62,500 2.50 0.40 312,500 0.50 0.08 1.00 - 1.99 750,000 1.25 1.00 750,000 1.25 1.00 2.00 650,000 1.25 2.00 650,000 1.25 2.00 $ 0.01 - 2.00 15,237,738 2.94 $ 0.27 12,012,738 2.79 $ 0.30 As of September 30, 2019, there were 14,762,262 shares of stock options remaining available for issuance under the 2010 Plan. Stock Warrants During the year ended September 30, 2018: ● The Company issued warrants to purchase 3,228,572 shares with exercise prices of $0.15 and $0.18 per share as part of the sale of equity units. The warrants expire five years from the date of grant. ● The Company issued warrants to purchase 1,100,000 shares with an exercise price of $0.20 per share in connection with the issuance of a convertible notes payable (see Note 5). The warrants expire five years from the date of grant. ● The Company issued warrants to purchase 6,038,336 shares with exercise prices of $0.14 and $0.18 per share in connection with the conversion of loans payable from officers and shareholders (see Note 4). ● The Company issued warrants to purchase 6,104,322 shares with an exercise price of $0.18 per share in connection with the initial equity agreement that included a favored nation’s clause and the settlement of that equity agreement. Also, in connection with the agreement, a warrant to purchase 1,600,000 shares was also cancelled with an exercise price of $0.40 per share. ● Warrants were exercised to purchase 1,407,619 shares of the Company’s common stock for $170,914. During the year ended September 30, 2019, the Company issued a warrant to purchase 284,714 shares with an exercise price of $0.15 per share as part of the sale of equity units. The warrant expires five years from the date The table below summarizes the Company’s warrants activities for the years ended September 30, 2019 and 2018: Number of Exercise Weighted Average Fair Value at Balance, September 30, 2017 64,161,304 $ 0.12 - 1.00 $ 0.24 $ 2,151,219 Granted 16,471,230 0.14 - 0.20 0.17 1,283,341 Canceled (1,600,000 ) 0.40 0.40 - Exercised (1,407,619 ) 0.12 – 0.15 0.12 - Expired (9,717,187 ) 0.30 - 2.31 0.56 - Balance, September 30, 2018 67,907,728 $ 0.12 - 1.00 $ 0.17 $ 3,434,560 Granted 284,714 0.15 0.15 - Cancelled - - - - Exercised - - - - Expired (1,708,393 ) 0.30 - 0.67 0.44 - Balance, September 30, 2019 66,484,049 $ 0.12 - 1.00 $ 0.17 $ 3,434,560 Vested and exercisable, September 30, 2019 66,484,049 $ 0.12 - 1.00 $ 0.17 $ 3,434,560 There was no aggregate intrinsic value for warrant shares outstanding at September 30, 2019. The following table summarizes information concerning outstanding and exercisable warrants as of September 30, 2019: Warrants Outstanding Warrants Exercisable Range of Exercise Prices Number Outstanding Average Remaining Contractual Life (in years) Weighted Average Exercise Price Number Exercisable Average Remaining Contractual Life (in years) Weighted Average Exercise Price $ 0.12 – 0.20 59,279,384 1.90 $ 0.15 59,279,384 1.90 $ 0.15 0.21 – 0.40 7,204,665 0.85 0.26 7,204,665 0.85 0.26 $ 0.12 – 0.40 66,484,049 1.79 $ 0.17 66,484,049 1.79 $ 0.17

Segment Reporting

Segment Reporting	12 Months Ended
	Sep. 30, 2019
Segment Reporting [Abstract]
Segment Reporting	NOTE 7 – SEGMENT REPORTING Reportable segments are components of an enterprise about which separate financial information is available and that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company’s reportable segments are based on products and services, geography, legal structure, management structure, or any other manner in which management disaggregates a company. The Company operates in the following business segments: (i) Medical Devices: (ii) Authentication and Encryption Products and Services: The detailed segment information of the Company is as follows: Assets By Segment September 30, 2019 Corporate Medical Devices Authentication and Encryption Total ASSETS Current Assets Cash $ 50,892 $ 846 $ 1,409 $ 53,147 Prepaid expenses and other current assets - 55,000 - 55,000 Total current assets 50,892 55,846 1,409 108,147 Property and equipment, net - - 1,562 1,562 Total other assets - - 1,562 1,562 TOTAL ASSETS $ 50,892 $ 55,846 $ 2,971 $ 109,709 Operations by Segment For the Year Ended September 30, 2019 Corporate Medical Devices Authentication and Encryption Total Sales: Trade $ - $ - $ 19,508 $ 19,508 Consulting services - - 13,867 13,867 Total Sales - - 33,375 33,375 Cost of goods sold - - 20,025 20,025 Gross profit - - 13,350 13,350 Operating expenses 782,961 641,236 355,737 1,779,934 Loss from operations $ (782,961 ) $ (641,236 ) $ (342,387 ) $ (1,766,584 ) Operations by Segment For the Year Ended September 30, 2018 Corporate Medical Devices Authentication and Encryption Total Sales: Trade $ - $ 45,000 $ 95,023 $ 140,023 Consulting services - - 73,700 73,700 Total Sales - 45,000 168,723 213,723 Cost of goods sold - - 79,960 79,960 Gross profit - 45,000 88,763 133,763 Operating expenses 1,179,937 224,196 822,229 2,226,362 Loss from operations $ (1,179,937 ) $ (179,196 ) $ (733,466 ) $ (2,092,599 )

Legal Matters

Legal Matters	12 Months Ended
	Sep. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Legal Matters	NOTE 8 – LEGAL MATTERS The Company is periodically engaged in legal proceedings arising from and relating to its business operations. We currently are not involved in any litigation that we believe could have a material adverse effect on our financial condition or results of operations. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of our Company or any of our subsidiaries, threatened against or affecting our Company, our common stock, any of our subsidiaries or of our Company’s or our subsidiaries’ officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect on our financial condition or results of operations. However, we recently decided to attempt to preserve revenue and reduce operating expenses through actions including, but not limited to, facilities consolidation and staff reductions, which we hope to implement through negotiated transactions with lessors, employees and other third parties. Such actions may result in disputes with and claims by such parties which, if not resolved through negotiations, may impact negatively the Company’s ability to continue as a going concern. To date, we have negotiated settlement of all but $89,302 in ex-employee wage and benefits claims, with agreement to pay such remaining amount, together with interest at the rate of 4% per annum on the principal amount from time to time outstanding, when and as cash flow permits. One of the employees claims additional amounts due for certain statutory damages under the Illinois Wage Payment and Collection which currently could exceed $21,600.00 and would increase at the rate of 2% of the wages due per month plus attorneys’ fees if the employee elects to file suit for a violation of the Act and is successful in obtaining a judgment on his claim. In periodic reports the Company disclosed that on May 25, 2017, the SEC’s Chicago Regional Office informed it that it had made a preliminary determination to recommend filing of an enforcement action against the Company and its CEO based on possible violations of Section 10(b) of the Exchange Act and Rule 10b-5 thereunder, and Section 17(a) of the Securities Act, and Section 15(a) of the Exchange Act. Subsequent discussions resulted in the submission of an Offer of Settlement (“Settlement”) through an administrative cease and desist action on November 17, 2017, which was accepted by the SEC on April 12, 2018, as disclosed on Form 8K filed April 18, 2018. Pursuant to the Settlement, the Company neither admitted nor denied any of the allegations, but was enjoined from violating the above-referenced Sections and Rule. The Settlement imposed no financial penalties or sanctions against the Company. The Form 8K also disclosed that on April 13, 2018, the SEC filed a separate complaint against the CEO in the U.S. District Court for the Northern District of Illinois, asserting the allegations noted above, as well as allegations that he manipulated the price of company shares through undisclosed trading, realizing more than $130,000 from such trading. On the date of filing, the CEO voluntarily resigned as an officer and director of the Company. Without admitting or denying the allegations, the CEO consented to the entry of the judgment, which was entered on September 26, 2018 by the U.S. District Court for the Northern District of Illinois. The judgment permanently enjoined him from violating the anti-fraud provisions of Section 17(a) of the Securities Act of 1933, Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder, and the broker registration provisions of Section 15(a) of the Exchange Act. It also bars him from serving as an officer or director of a public company and from participating in penny stock offerings, and ordered disgorgement and interest and penalties to be determined by the court. On January 31, 2019, the former CEO was terminated and his service as Director of Business Development ceased as of that date.

Commitments

Commitments	12 Months Ended
	Sep. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments	NOTE 9 – COMMITMENTS Operating Leases The Company leased its corporate office facility in Hoffman Estates, Illinois pursuant to a non-cancellable lease initiated in July 2016 and expiring February 28, 2024. The lease terms require a monthly payment of approximately $11,000. The Company vacated the facility in April 2019, in favor of its present facilities in Tucson AZ, which are provided by a shareholder on a rent-free basis. The Company is in negotiations with the owners regarding the settlement of its lease obligations and expects that the property will be subleased or a settlement with the landlord will be reached at an amount significantly less than the remaining payment obligations. At the date of abandonment, the Company had a remaining lease obligation of $631,587. During the year ended September 30, 2019, the Company recorded an accrual for the estimated potential settlement and wrote-off its $15,000 security deposit relating to the lease. Commencing on October 1, 2016, the Company’s wholly-owned subsidiary, StealthCo, entered into a non-cancellable lease agreement to lease its office facilities in Oak Ridge, Tennessee. The term of the lease is five years and expires September 30, 2021. On January 6, 2020, the Company entered into an agreement with the owners to terminate the agreement effective January 1, 2020. Under the agreement, the Company agreed to pay $11,000 and abandon certain Company property to the owners as documented in the agreement. In February 2019, the Company’s wholly-owned subsidiary, Psoria Shield, entered into a non-cancellable lease agreement to lease its office facilities in Utica, New York. The term of the lease is two years and expires February 8, 2021. Minimum annual rental commitments for Psoria Shield under non-cancelable leases at September 30, 2019, excluding the office facility lease in Hoffman Estates, Illinois, are as follows: Years ending September 30, Amount 2020 $ 21,600 2021 7,200 TOTAL $ 28,800 Rent expense was $180,946 and $188,801 for the years ended September 30, 2019 and 2018, respectively. Employment Contracts During the year ended September 30, 2018, the Company entered into employment agreements with four employees of StealthCo (including Ricky Howard), under which their employment shall continue in effect for a period of three years. Each agreement allows for a base salary with an accumulated amount of $350,000 that can increase each year based on certain profitability goals of SCI or SCI products. Under the agreements, the Company will issue options to purchase shares of its common stock as discussed in Note 6. As of September 30, 2019, one of the employees was still employed by the Company.

Income Taxes

Income Taxes	12 Months Ended
	Sep. 30, 2019
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 10 – INCOME TAXES At September 30, 2019, the Company had net operating loss (“NOL”) carryforwards for federal income tax purposes of approximately $18 million that may be offset against future taxable income through 2038. No tax benefit has been reported with respect to these net operating loss (NOL) carryforwards because the Company believes that the realization of the Company’s net deferred tax assets of approximately $4,000,000 was not considered more likely than not and accordingly, the potential tax benefits of the net loss carryforwards are offset by a full valuation allowance. The Company recognizes as income tax expense, interest and penalties on uncertain tax provisions. As of September 30, 2019, and 2018, the Company has not accrued interest or penalties related to uncertain tax positions. Tax years 2015 through 2018 remain open to examination by the major taxing jurisdictions to which the Company is subject. The Company’s effective income tax rate differs from the amount computed by applying the federal statutory income tax rate to loss before income taxes as follows: September 30, September 30, Income tax benefit at federal statutory rate (21.0 )% (21.0 )% State income tax benefit, net of federal benefit (4.0 )% (4.0 )% Change in valuation allowance 25.0 % 25.0 % Income taxes at effective income tax rate - % - % The components of deferred taxes consist of the following at September 30, 2019 and 2018: September 30, September 30, Net operating loss carryforwards $ 4,657,556 $ 4,307,629 Less: Valuation allowance (4,657,556 ) (4,307,629 ) Net deferred tax assets $ - $ -

Related Party Transactions

Related Party Transactions	12 Months Ended
	Sep. 30, 2019
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 11 – RELATED PARTY TRANSACTIONS Compensation of Former Chairman and Chief Executive Officer During the year ended September 30, 2018, the Company’s former Chairman and Chief Executive Officer, Andrew J. Kandalepas, was paid compensation $182,375 and was granted stock options to purchase 1,300,000 shares of the Company’s common stock at an exercise price of $0.14 per share. The options expire five years from the date of grant and the shares will vest in various periods. Mr. Kandalepas resigned as an officer and director in April 2018, but continued to be employed as Director of Business Development through January 2019. During the year ended September 30, 2019, Mr. Kandalepas was paid compensation of $133,333. As of September 30, 2019 and 2018, $33,964 and $81,965 of accrued compensation, respectively, was owed to Mr. Kandalepas. Corporate Office Facility The Company leased its corporate office facility in Hoffman Estates, Illinois pursuant to a non-cancellable lease initiated in July 2016 and expiring February 28, 2024. The Company vacated the facility in April 2019, in favor of its present facilities in Tucson AZ, which are provided by a shareholder on a rent-free basis.

Proposed Sale of Stealthco, Inc

Proposed Sale of Stealthco, Inc.	12 Months Ended
	Sep. 30, 2019
Proposed Sale Of Stealthco Inc.
Proposed Sale of Stealthco, Inc.	NOTE 12 – PROPOSED SALE OF STEALTHCO, INC. On September 3, 2019, the Company’s Board of Directors unanimously approved, subject to stockholder approval: (1) execution and delivery of a proposed Share Exchange Agreement with DTI Holdings, Inc. (“DTI”) relating to the share exchange and transfer of certain assets of StealthCo, Inc. (“SCI”) pursuant to the terms and conditions of a Memorandum of Agreement in substantially the form of the copy presented to the Board (“Agreement”). As of September 18, 2019, holders of a majority of the outstanding shares of voting capital stock have executed written stockholder consents approving this action. The Agreement provides, among other things, that: (1) DTI will pay the Company $500,000 upon the execution of a definitive share exchange agreement (“Share Exchange Agreement”) which the parties will endeavor to negotiate and execute as quickly as possible, and not later than October 15, 2019; (2) DTI will pay the Company an additional $500,000 within seven days following the completion date of the transfer of all assets and/or full ownership of SCI to DTI, with such date to occur within 120 days following execution of the Share Exchange Agreement; (3) DTI will issue to the Company 3,112,000 shares of DTI common stock and will guaranty that the value of the 3,112,000 shares of DTI common stock will have a value of at least $4.50 per share ($14,004,000, in the aggregate), as of December 31, 2021; (4) To the extent that the value of the DTI common shares, as of December 31, 2021, is less than $4.50 per share ($14,004,000, in the aggregate), DTI will issue additional shares of DTI common stock, at the then current fair market value, in an amount sufficient to cause the resulting aggregate value of all shares of DTI common stock issued to the Company to be $14,004,000, in the aggregate; (5) DTI will assign the assets transferred by SCI, including trademarks, intellectual properties, and patents, to its subsidiary, Femtobitz, Inc., a Delaware corporation, and will pay to the Company 1% of annual gross revenue arising from or relating to operation of Femtobitz, Inc.; and (6) Upon closing of the share exchange, the Company’s Chairman will be appointed an advisory board member of DTI and a board member of Femtobitz, Inc. As of September 18, 2019, stockholders holding a majority of our outstanding common stock approved the share exchange and the Company began discussions and negotiations with DTI, which are currently on-going as of the date of this filing. There can be no assurance that the proposed transaction will be concluded successfully on the terms described or any alternate terms that may be proposed hereafter.

Subsequent Events

Subsequent Events	12 Months Ended
	Sep. 30, 2019
Subsequent Events [Abstract]
Subsequent Events	NOTE 13 – SUBSEQUENT EVENTS Subsequent to September 30, 2019, the Company borrowed $310,000 from its officers and shareholders. All of the loans are unsecured, have an interest rate of eight percent and are due one year from the date of issuance. Subsequent to September 30, 2019, an additional $50,000 was contributed by GEN2 to NEO and as of December 31, 2019, GEN2 had received $975,000 of investments to contribute to NEO (see Note 2). Commencing on October 1, 2016, the Company’s wholly-owned subsidiary, StealthCo, entered into a non-cancellable lease agreement to lease its office facilities in Oak Ridge, Tennessee. The term of the lease is five years and expires September 30, 2021. On January 6, 2020, the Company entered into an agreement with the owners to terminate the agreement effective January 1, 2020. Under the agreement, the Company agreed to pay $11,000 and abandon certain Company property as documented in the agreement. Effective January 1, 2020, the Company’s Board of Directors approved the extension of the Company’s unexpired stock warrants as of December 31, 2019, by an additional one year period. This change would affect approximately 66 million warrant shares and approximately 20 million warrant shares that were set to expire by the year ending September 30, 2020. The 20 million warrant shares that were set to expire by September 30, 2020, had exercise prices ranging from $0.15 per share to $0.25 per share. The 66 million warrant shares had exercise prices ranging from $0.12 per share to $0.40 per share. The incremental fair value of the warrants resulting from modification is approximately $700,000 that will be recognized as an expense during the period ending March 31, 2020.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Basis of Consolidation	Basis of Consolidation The Company’s consolidated subsidiaries and/or entities are as follows: Name of consolidated subsidiary or entity State or other jurisdiction of incorporation or organization Date of incorporation or formation (date of acquisition/disposition, if applicable) Attributable interest Psoria-Shield Inc. (“PSI”) The State of Florida June 17, 2009 100 % StealthCo, Inc. (“StealthCo”) The State of Illinois March 18, 2014 100 % Psoria Development Company LLC. (“PDC”) The State of Illinois January 15, 2015 50 % NEO Phototherapy LLC (“NEO”) The State of Illinois December 2018 50.5 %
Use of Estimates	Use of Estimates The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the financial statement date, and reported amounts of revenue and expenses during the reporting period. Significant estimates are used in the valuation of accounts receivable and allowance for uncollectible amounts, inventory and obsolescence reserves, accruals for potential liabilities, valuations of stock-based compensation, realization of deferred tax assets, among others. Actual results could differ from these estimates.
Income (loss) Per Share	Income (Loss) Per Share Basic loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of outstanding common shares during the period. Diluted loss per share is computed by dividing the net loss applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued. For the years ended September 30, 2019 and 2018, the basic and diluted shares outstanding were the same, as potentially dilutive shares were considered anti-dilutive. At September 30, 2019 and 2018, the dilutive impact of outstanding stock options of 15,237,738 and 17,946,667 shares, respectively, and outstanding warrants for 66,484,049 and 67,907,728 shares, respectively, have been excluded because their impact on the loss per share is anti-dilutive.
Revenue Recognition	Revenue Recognition In May 2014, the FASB issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (Topic 606). For trade sales, the Company generates its revenue from sales contracts with customers with revenues being generated upon the shipment of merchandise, or for c We sell our products through two main sales channels: 1) directly to customers who use our products (the “Direct Channel”) and 2) to distribution partners who resell our products (the “Indirect Channel”). Under the Direct Channel, we sell our products to and we receive payment directly from customers who purchase our products. Under our Indirect Channel, we have entered into distribution agreements that allow the distributors to sell our products and fulfill performance obligations under the agreements. We determine revenue recognition through the following steps: ● Identification of the contract, or contracts, with a customer ● Identification of the performance obligations in the contract ● Determination of the transaction price ● Allocation of the transaction price to the performance obligations in the contract ● Recognition of revenue when, or as, we satisfy a performance obligation. Revenue is generally recognized upon shipment or when a service has been completed, unless we have significant performance obligations for services still to be completed. We recognize revenue when a material reversal is no longer probable. Payments received before the relevant criteria for revenue recognition are satisfied are recorded as deferred revenue. Deferred revenue at September 30, 2018 was $8,624. There was no deferred revenue at September 30, 2019.
Property and Equipment	Property and Equipment Property and equipment are carried at cost less accumulated depreciation and amortization. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. The Company has determined the estimated useful lives of its property and equipment, as follows: Computer equipment 5 years Medical equipment 5 years Furniture and fixtures 7 years Vehicles 3 years Software 3 years Maintenance and repairs are charged to expense as incurred. The cost and accumulated depreciation of assets sold or otherwise disposed of are removed from the related accounts and the resulting gain or loss is reflected in the statements of operations. Management assesses the carrying value of property and equipment whenever events or changes in circumstances indicate that the carrying value may not be recoverable. If there is indication of impairment, management prepares an estimate of future cash flows expected to result from the use of the asset and its eventual disposition. If these cash flows are less than the carrying amount of the asset, an impairment loss is recognized to write down the asset to its estimated fair value.
Income Taxes	Income Taxes Income tax expense is based on pretax financial accounting income. Deferred tax assets and liabilities are recognized for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts. Valuation allowances are recorded to reduce deferred tax assets to the amount that will more likely than not be realized. The Company recorded a valuation allowance against its deferred tax assets as of September 30, 2019 and 2018. The Company accounts for uncertainty in income taxes using a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50 percent likely of being realized upon settlement. The Company classifies the liability for unrecognized tax benefits as current to the extent that the Company anticipates payment (or receipt) of cash within one year. Interest and penalties related to uncertain tax positions are recognized in the provision for income taxes.
Fair Value Measurements	Fair Value measurements The Company determines the fair value of its assets and liabilities based on the exchange price in U.S. dollars that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The Company uses a fair value hierarchy with three levels of inputs, of which the first two are considered observable and the last unobservable, to measure fair value: ● Level 1 — ● Level 2 — ● Level 3 — The carrying amounts of financial instruments such as cash, and accounts payable and accrued liabilities, approximate the related fair values due to the short-term maturities of these instruments.
Non-controlling Interests	Non-controlling Interest Through November 2018, non-controlling interest represented the non-controlling interest holder’s proportionate share of the equity of the Company’s majority-owned subsidiary, PDC. Non-controlling interest is adjusted for the non-controlling interest holder’s proportionate share of the earnings or losses and other comprehensive income (loss), if any, and the non-controlling interest continues to be attributed its share of losses even if that attribution results in a deficit non-controlling interest balance. On November 15, 2018, PSI and TMA entered into a Withdraw and Mutual Release Agreement to terminate their joint venture agreement. On the date of termination, the non-controlling interest’s share of the accumulated losses of the joint venture totaled to $405,383. Upon termination, during the three months ended December 31, 2018, the Company wrote-off the non-controlling interest’s share of the accumulated losses and recorded a loss from the deconsolidation of a non-controlling interest of $405,383. In December 2018, PSI entered into a Joint Venture Agreement with GEN2 to further development, marketing, licensing and/or sale of PSI technology and products. Pursuant to the Joint Venture Agreement, the venture will be conducted through NEO. PSI and GEN2 will be the members of NEO, owning 50.5% and 36.0%, respectively, of the Units issued in connection with the organization of NEO. An additional 13.5% of such Units will be reserved for issuance as incentives for key employees and consultants. Until such shares are distributed, the Company controls 68% of the joint venture and GEN2 the remaining 32%. PSI and GEN2 will manage NEO’s day-to-day operations. PSI will contribute PSI technology to NEO and GEN2 will contribute $700,000. As of September 30, 2019, NEO’s operations required additional funding above the $700,000 documented in the agreement, and as of September 30, 2019, GEN2 had received $925,000 of investments to contribute to NEO. As of September 30, 2019, the Company controlled 51% of the joint venture, GEN2 controlled 39% and another individual controlled the remaining 10%. The Company recorded its proportionate share of the contributions received of $471,750 to additional paid-in-capital and $453,250 to non-controlling interest as of that date. During the year ended September 30, 2019, NEO recorded a loss of $122,655 relating to its operations. Repayment of the investment by GEN2 will begin through and upon the date which NEO has realized and retained cumulative net income/distributable cash in the amount of $300,000. Distributions thereafter will be made to PSI, GEN2 and other members in proportion to their respective Unit ownership, at the times and in the manner determined from time to time by the managers, in their sole discretion. GEN2 consists of accredited investors, and investment participation of $700,000 from several WCUI officers and directors, including Calvin R. O’Harrow and Roy M. Harsch.
Stock-based Compensation	Stock-Based Compensation The Company periodically grants stock options and warrants to employees and non-employees in non-capital raising transactions as compensation for services rendered. The Company accounts for stock option and stock warrant grants to employees based on the authoritative guidance provided by the Financial Accounting Standards Board where the value of the award is measured on the date of grant and recognized over the vesting period. The Company accounts for stock option and stock warrant grants to non-employees in accordance with the authoritative guidance of the Financial Accounting Standards Board where the value of the stock compensation is determined based upon the measurement date at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Non-employee stock-based compensation charges generally are amortized over the vesting period on a straight-line basis. In certain circumstances where there are no future performance requirements by the non-employee, option or warrant grants are immediately vested and the total stock-based compensation charge is recorded in the period of the measurement date. The fair value of the Company’s common stock option and warrant grants are estimated using a Black-Scholes Merton option pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the common stock options, estimated forfeitures and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes option pricing model, and based on actual experience. The assumptions used in the Black-Scholes Merton option pricing model could materially affect compensation expense recorded in future periods.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In February 2016, the FASB issued Accounting Standards Update (ASU) No. 2016-02, Leases. ASU 2016-02 requires a lessee to record a right of use asset and a corresponding lease liability on the balance sheet for all leases with terms longer than 12 months. ASU 2016-02 is effective for all interim and annual reporting periods beginning after December 15, 2018. Early adoption is permitted. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is in the process of evaluating the impact of ASU 2016-02 on the Company’s financial statements and disclosures. In June 2018, the FASB issued ASU No. 2018-07, “Compensation - Stock Compensation (Topic 718); Improvements to Non-Employee Share-Based Payment Accounting” (“ASU 2018-07”). ASU 2018-07 generally aligns the measurement and classification of share-based awards to non-employees with that of share-based awards to employees. Non-employee equity awards will be measured at the fair value of the equity instruments to be issued, as of the grant date, and the resulting amount will be recognized as expense over the expected or contractual term of the award. The ASU applies to all share-based payments to nonemployees in exchange for goods or services used or consumed in an entity’s own operations. It does not apply to instruments issued to a lender or investor in a financing transaction, or to instruments granted when selling goods or services to customers. ASU 2018-07 is effective for annual periods beginning after December 15, 2018, and interim periods within those annual periods. Early adoption is permitted. The Company is currently evaluating the expected impact that the standard could have on its financial statements and related disclosures. Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Schedule of Company's Consolidated Subsidiaries	The Company’s consolidated subsidiaries and/or entities are as follows: Name of consolidated subsidiary or entity State or other jurisdiction of incorporation or organization Date of incorporation or formation (date of acquisition/disposition, if applicable) Attributable interest Psoria-Shield Inc. (“PSI”) The State of Florida June 17, 2009 100 % StealthCo, Inc. (“StealthCo”) The State of Illinois March 18, 2014 100 % Psoria Development Company LLC. (“PDC”) The State of Illinois January 15, 2015 50 % NEO Phototherapy LLC (“NEO”) The State of Illinois December 2018 50.5 %
Schedule of Estimated Useful Lives of Property and Equipment	The Company has determined the estimated useful lives of its property and equipment, as follows: Computer equipment 5 years Medical equipment 5 years Furniture and fixtures 7 years Vehicles 3 years Software 3 years

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Sep. 30, 2019
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment consisted of the following at September 30, 2019 and 2018: September 30, 2019 September 30, 2018 Vehicles $ 15,000 $ 15,000 Computer equipment 10,456 10,456 Furniture and fixtures 23,998 23,998 Medical equipment 18,889 18,889 Software 23,207 23,207 Leasehold improvements 15,170 15,170 106,720 106,720 Less: accumulated depreciation and amortization (105,158 ) (104,101 ) Property and equipment, net $ 1,562 $ 2,619

Convertible Note Agreements (Ta

Convertible Note Agreements (Tables)	12 Months Ended
	Sep. 30, 2019
Debt Disclosure [Abstract]
Schedule of Convertible Notes Payable	Convertible notes payable consisted of the following at September 30, 2019 and 2018: September 30, 2019 September 30, 2018 Convertible note payable (a) $ - $ 165,000 Convertible note payable (b) - 110,000 Debt discount – unamortized balance - (72,078 ) Convertible notes payable, net $ - $ 202,922 (a) On March 5, 2018, the Company entered into a Convertible Note Payable Agreement with an individual under which the Company borrowed $165,000. Net proceeds received by the Company under the agreement after payment of a $15,000 fee to the lender was $150,000. In connection with the agreement, the Company issued the individual 300,000 restricted shares of its common stock with a fair value of $48,000 and warrants to purchase 660,000 shares of its common stock, which vested upon grant. The warrants expire five years from the date of grant and have an exercise price of $0.20 per share. The note payable accrues interest at eight percent per annum, is unsecured and is convertible at any time after the 90th day from the issue date into the Company’s common stock at the fixed conversion price of $0.10 per share. The note matured in October 2018. The Company calculated the related fair value of the warrants issued to the noteholder to be $55,032 using a Black Scholes Merton option pricing model and performing a relative value calculation. The Company then made a calculation to determine if a beneficial conversion feature (BCF) existed. The beneficial conversion was based upon the effective conversion price based on the proceeds received that were allocated to the convertible instrument. Based upon the Company’s calculation, it was determined that a beneficial conversion feature existed amounting to $94,968 and was recorded as a debt discount. As such the Company recognized a debt discount at the date of issuance in the aggregate amount of $165,000 relating to the $15,000 fees paid to the lender, the relative value of the warrants and the BCF. The note discount is being amortized over the term of the note and the unamortized portion is recognized as a reduction to the carrying amount of the Convertible note (a valuation debt discount). The balance of the unamortized discount at September 30, 2018 was $3,837. During the year ended September 30, 2019, the Company amended the terms of the agreement by extending the maturity date to January 2019 and reducing the conversion price from $0.10 per share to $0.07 per share. The reduction of the conversion price caused the Company to issue an additional 744,732 shares, which on the dates of amendment had a combined total fair value of $51,434, which was recorded a financing cost during the year ended September 30, 2019. During the year ended September 30, 2019, the individual converted $165,000 of the convertible note payable and $8,783 of accrued interest into 2,482,441 shares of the Company’s common stock. During the year ended September 30, 2019, the Company amortized the remaining $3,837 of debt discount, leaving no unamortized balance at September 30, 2019. No amounts were outstanding under the agreement as of September 30, 2019. (b) On July 11, 2018, the Company entered into another Convertible Note Payable Agreement with the same individual under which the Company borrowed an additional $110,000. Net proceeds received by the Company under the agreement after payment of a $10,000 fee to the lender was $100,000. In connection with the agreement, the Company issued the individual 200,000 restricted shares of its common stock with a fair value of $36,000 and warrants to purchase 440,000 shares of its common stock, which vested upon grant. The warrants expire five years from the date of grant and have an exercise price of $0.18 per share. The note payable accrues interest at eight percent per annum, is unsecured and is convertible at any time after the 90th day from the issue date into the Company’s common stock at the fixed conversion price of $0.15 per share. The note matures in February 2019, but may be extended at the option of the individual. The Company may prepay the note at any time immediately following the issue date upon seven days’ prior written notice. The note was converted into shares of the Company’s common stock (see below). The Company calculated the related fair value of the warrants issued to the noteholder to be $66,440 using a Black Scholes Merton option pricing model and performing a relative value calculation. The Company then made a calculation to determine if a beneficial conversion feature (BCF) existed. The beneficial conversion was based upon the effective conversion price based on the proceeds received that were allocated to the convertible instrument. Based upon the Company’s calculation, it was determined that a beneficial conversion feature existed amounting to $33,560 and was recorded as a debt discount. As such the Company recognized a debt discount at the date of issuance in the aggregate amount of $110,000 relating to the $10,000 fees paid to the lender, the relative value of the warrants and the BCF. The note discount is being amortized over the term of the note and the unamortized portion is recognized as a reduction to the carrying amount of the Convertible note (a valuation debt discount). As of September 30, 2018, the Company had amortized $41,759 of debt discount, leaving an unamortized balance of $68,241 at September 30, 2018. During the year ended September 30, 2019, the Company amended the terms of the agreement by reducing the conversion price from $0.15 per share to $0.05 per share. The reduction of the conversion price caused the Company to issue an additional 1,551,854 shares, which on the date of amendment had a fair value of $108,630, which was recorded a financing cost during the year ended September 30, 2019. During the year ended September 30, 2019, the Company amortized $68,241 of debt discount, leaving no unamortized balance at September 30, 2019. On April 2, 2019, the individual converted the note payable of $110,000 and $6,389 of accrued interest into 2,327,781 shares of the Company’s common stock. No amounts were outstanding under the agreement as of September 30, 2019.

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	12 Months Ended
	Sep. 30, 2019
Equity [Abstract]
Schedule of Assumptions Used for Options Granted	The assumptions used for options granted during the year ended September 30, 2018 are as follows: Exercise price $ 0.10 - 0.19 Expected dividends - Expected volatility 121.1% - 130.2 % Risk free interest rate 2.01% - 2.85 % Expected life of options 2.5 The assumptions used for options granted during the year ended September 30, 2019 are as follows: Exercise price $ 0.03 - 0.06 Expected dividends - Expected volatility 126.8% - 144.0 % Risk free interest rate 1.60% - 2.47 % Expected life of options 2.5
Schedule of Stock Option Activity	The table below summarizes the Company’s stock option activities for the years ended September 30, 2019 and 2018: Number of Exercise Weighted Average Fair Value Balance, September 30, 2017 6,822,500 $ 0.10 – 2.00 $ 0.51 $ 1,865,628 Granted 11,317,500 0.10 – 0.19 0.14 1,379,127 Cancelled (183,333 ) 0.14 0.14 - Exercised - - - - Expired (10,000 ) 0.75 0.75 - Balance, September 30, 2018 17,946,667 $ 0.10 - 2.00 $ 0.28 $ 3,244,755 Granted 250,000 0.03 - 0.06 0.05 10,366 Cancelled (646,429 ) 0.14 – 0.19 0.17 - Exercised - - - - Expired (2,312,500 ) 0.13 – 0.40 0.37 - Balance, September 30, 2019 15,237,738 $ 0.03 – 2.00 $ 0.27 $ 3,255,121 Vested and exercisable, September 30, 2019 12,012,738 $ 0.03 - 2.00 $ 0.30 $ 2,803,621 Unvested, September 30, 2019 3,225,000 $ 0.14 $ 0.14 $ 451,500
Schedule of Outstanding and Exercisable Options by Exercise Price Range	The following table summarizes information concerning outstanding and exercisable options as of September 30, 2019: Options Outstanding Options Exercisable Range of Exercise Prices Number Outstanding Average Remaining Contractual Life (in years) Weighted Average Exercise Price Number Exercisable Average Remaining Contractual Weighted Average Exercise Price $ 0.01 - 0.39 13,775,238 3.11 $ 0.15 10,300,238 3.07 $ 0.15 0.40 - 0.99 62,500 2.50 0.40 312,500 0.50 0.08 1.00 - 1.99 750,000 1.25 1.00 750,000 1.25 1.00 2.00 650,000 1.25 2.00 650,000 1.25 2.00 $ 0.01 - 2.00 15,237,738 2.94 $ 0.27 12,012,738 2.79 $ 0.30
Schedule of Warrant Activity	The table below summarizes the Company’s warrants activities for the years ended September 30, 2019 and 2018: Number of Exercise Weighted Average Fair Value at Balance, September 30, 2017 64,161,304 $ 0.12 - 1.00 $ 0.24 $ 2,151,219 Granted 16,471,230 0.14 - 0.20 0.17 1,283,341 Canceled (1,600,000 ) 0.40 0.40 - Exercised (1,407,619 ) 0.12 – 0.15 0.12 - Expired (9,717,187 ) 0.30 - 2.31 0.56 - Balance, September 30, 2018 67,907,728 $ 0.12 - 1.00 $ 0.17 $ 3,434,560 Granted 284,714 0.15 0.15 - Cancelled - - - - Exercised - - - - Expired (1,708,393 ) 0.30 - 0.67 0.44 - Balance, September 30, 2019 66,484,049 $ 0.12 - 1.00 $ 0.17 $ 3,434,560 Vested and exercisable, September 30, 2019 66,484,049 $ 0.12 - 1.00 $ 0.17 $ 3,434,560
Schedule of Outstanding and Exercisable Warrants by Exercise Price Range	The following table summarizes information concerning outstanding and exercisable warrants as of September 30, 2019: Warrants Outstanding Warrants Exercisable Range of Exercise Prices Number Outstanding Average Remaining Contractual Life (in years) Weighted Average Exercise Price Number Exercisable Average Remaining Contractual Life (in years) Weighted Average Exercise Price $ 0.12 – 0.20 59,279,384 1.90 $ 0.15 59,279,384 1.90 $ 0.15 0.21 – 0.40 7,204,665 0.85 0.26 7,204,665 0.85 0.26 $ 0.12 – 0.40 66,484,049 1.79 $ 0.17 66,484,049 1.79 $ 0.17

Segment Reporting (Tables)

Segment Reporting (Tables)	12 Months Ended
	Sep. 30, 2019
Segment Reporting [Abstract]
Schedule of Assets of Reportable Segments	The detailed segment information of the Company is as follows: Assets By Segment September 30, 2019 Corporate Medical Devices Authentication and Encryption Total ASSETS Current Assets Cash $ 50,892 $ 846 $ 1,409 $ 53,147 Prepaid expenses and other current assets - 55,000 - 55,000 Total current assets 50,892 55,846 1,409 108,147 Property and equipment, net - - 1,562 1,562 Total other assets - - 1,562 1,562 TOTAL ASSETS $ 50,892 $ 55,846 $ 2,971 $ 109,709
Schedule of Operations of Reportable Segments	Operations by Segment For the Year Ended September 30, 2019 Corporate Medical Devices Authentication and Encryption Total Sales: Trade $ - $ - $ 19,508 $ 19,508 Consulting services - - 13,867 13,867 Total Sales - - 33,375 33,375 Cost of goods sold - - 20,025 20,025 Gross profit - - 13,350 13,350 Operating expenses 782,961 641,236 355,737 1,779,934 Loss from operations $ (782,961 ) $ (641,236 ) $ (342,387 ) $ (1,766,584 ) Operations by Segment For the Year Ended September 30, 2018 Corporate Medical Devices Authentication and Encryption Total Sales: Trade $ - $ 45,000 $ 95,023 $ 140,023 Consulting services - - 73,700 73,700 Total Sales - 45,000 168,723 213,723 Cost of goods sold - - 79,960 79,960 Gross profit - 45,000 88,763 133,763 Operating expenses 1,179,937 224,196 822,229 2,226,362 Loss from operations $ (1,179,937 ) $ (179,196 ) $ (733,466 ) $ (2,092,599 )

Commitments (Tables)

Commitments (Tables)	12 Months Ended
	Sep. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Summary of Minimum Annual Rental Commitments Under Non-cancelable Leases	Minimum annual rental commitments for Psoria Shield under non-cancelable leases at September 30, 2019, excluding the office facility lease in Hoffman Estates, Illinois, are as follows: Years ending September 30, Amount 2020 $ 21,600 2021 7,200 TOTAL $ 28,800

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Sep. 30, 2019
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate Reconciliation	The Company’s effective income tax rate differs from the amount computed by applying the federal statutory income tax rate to loss before income taxes as follows: September 30, September 30, Income tax benefit at federal statutory rate (21.0 )% (21.0 )% State income tax benefit, net of federal benefit (4.0 )% (4.0 )% Change in valuation allowance 25.0 % 25.0 % Income taxes at effective income tax rate - % - %
Schedule of Deferred Tax Assets and Liabilities	The components of deferred taxes consist of the following at September 30, 2019 and 2018: September 30, September 30, Net operating loss carryforwards $ 4,657,556 $ 4,307,629 Less: Valuation allowance (4,657,556 ) (4,307,629 ) Net deferred tax assets $ - $ -

Basis of Presentation (Details

Basis of Presentation (Details Narrative) - USD ($)	12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2017
Entity incorporation, state country name	Nevada
Net loss	$ (2,046,024)	$ (3,493,419)
Cash used in operations	(1,219,313)	(1,037,073)
Shareholders' deficit	(1,083,994)	(825,160)	$ (290,449)
Cash on hand	53,147	$ 4,210
Officers and Directors [Member]
Proceeds from loans payable, contributions capital by joint venture partner and the sale of common stock	1,293,250
Shareholder [Member]
Advances from shareholders	$ 310,000

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	Nov. 15, 2018	Sep. 30, 2019	Dec. 31, 2018	Dec. 31, 2018	Jun. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Deferred revenue							$ 8,624
Measurement of tax benefit, percentage of realized upon settlement, minimum, description						More than 50 percent
Non-controlling interest's share of accumulated losses of joint venture	$ 405,383
Loss from deconsolidation of non-controlling interest				$ 405,383		$ 405,383
Noncontrolling interest, description			Pursuant to the Joint Venture Agreement, the venture will be conducted through NEO. PSI and GEN2 will be the members of NEO, owning 50.5% and 36.0%, respectively, of the Units issued in connection with the organization of NEO. An additional 13.5% of such Units will be reserved for issuance as incentives for key employees and consultants. Until such shares are distributed, the Company controls 68% of the joint venture and GEN2 the remaining 32%. PSI and GEN2 will manage NEO's day-to-day operations. PSI will contribute PSI technology to NEO and GEN2 will contribute $700,000. Repayment of the investment by GEN2 will begin through and upon the date which NEO has realized and retained cumulative net income/distributable cash in the amount of $300,000.
Contributed capital			$ 700,000
Repayment of investments			700,000
Joint venture percentage		51.00%				51.00%
Additional paid-in capital		$ 23,777,647				$ 23,777,647	22,450,252
Non-controlling interest		393,149				393,149	(401,624)
Operating loss					$ (2,092,599)	(1,766,584)	$ (2,092,599)
Distributable cash			$ 300,000	$ 300,000
NEO [Member]
Additional funding						700,000
GEN2 [Member]
Investments to others		$ 925,000				$ 925,000
Joint venture percentage		39.00%				39.00%
Employees and Consultants [Member]
Additional units reserved for issuance			13.50%
Individual [Member]
Joint venture percentage		10.00%				10.00%
Psoria-Shield, Inc [Member]
Ownership percentage		50.50%				50.50%
Gen 2 Funding, Inc [Member]
Ownership percentage		36.00%				36.00%
Proceeds from investment		$ 700,000
Illinois Limited Liability Company [Member]
Additional paid-in capital		471,750				$ 471,750
Non-controlling interest		$ 453,250				453,250
Operating loss						$ 122,655
Stock Option [Member]
Antidilutive securities excluded from computation of earnings per share						15,237,738	17,946,667
Warrants [Member]
Antidilutive securities excluded from computation of earnings per share						66,484,049	67,907,728

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Company's Consolidated Subsidiaries (Details)	12 Months Ended
	Sep. 30, 2019
State or other jurisdiction of incorporation or organization	Nevada
Psoria-Shield, Inc [Member]
Name of consolidated subsidiary or entity	Psoria-Shield Inc. ("PSI")
State or other jurisdiction of incorporation or organization	The State of Florida
Date of incorporation or formation	Jun. 17, 2009
Date of acquisition/disposition	Aug. 24, 2012
Attributable interest	100.00%
StealthCo, Inc. [Member]
Name of consolidated subsidiary or entity	StealthCo, Inc. ("StealthCo")
State or other jurisdiction of incorporation or organization	The State of Illinois
Date of incorporation or formation	Mar. 18, 2014
Attributable interest	100.00%
Psoria Development Company LLC. [Member]
Name of consolidated subsidiary or entity	Psoria Development Company LLC. ("PDC")
State or other jurisdiction of incorporation or organization	The State of Illinois
Date of incorporation or formation	Jan. 15, 2015
Attributable interest	50.00%
NEO Phototherapy, LLC, [Member]
Name of consolidated subsidiary or entity	NEO Phototherapy LLC ("NEO")
State or other jurisdiction of incorporation or organization	The State of Illinois
Date of incorporation or formation	Dec. 31, 2018
Attributable interest	50.50%

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Property and Equipment (Details)	12 Months Ended
	Sep. 30, 2019
Computer Equipment [Member]
Estimated useful lives of property and equipment	5 years
Medical Equipment [Member]
Estimated useful lives of property and equipment	5 years
Furniture and Fixtures [Member]
Estimated useful lives of property and equipment	7 years
Vehicles [Member]
Estimated useful lives of property and equipment	3 years
Software [Member]
Estimated useful lives of property and equipment	3 years

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($)	12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 1,057	$ 2,507

Property and Equipment - Schedu

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	Sep. 30, 2019	Sep. 30, 2018
Property and equipment, gross	$ 106,720	$ 106,720
Less: accumulated depreciation and amortization	(105,158)	(104,101)
Property and equipment, net	1,562	2,619
Vehicles [Member]
Property and equipment, gross	15,000	15,000
Computer Equipment [Member]
Property and equipment, gross	10,456	10,456
Furniture and Fixtures [Member]
Property and equipment, gross	23,998	23,998
Medical Equipment [Member]
Property and equipment, gross	18,889	18,889
Software [Member]
Property and equipment, gross	23,207	23,207
Leasehold Improvements [Member]
Property and equipment, gross	$ 15,170	$ 15,170

Loans Payable from Officers a_2

Loans Payable from Officers and Shareholders (Details Narrative) - USD ($)	12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Nov. 30, 2018	Sep. 30, 2017
Proceeds from short term debt	$ 358,250	$ 434,500
Repayments of short term debt	$ 25,000	20,500
Number of warrants issued to purchase shares	284,714
Fair value of additional shares issued upon conversion of loans payable from officers and shareholders		30,583
Loans payable from officers and shareholders	$ 399,250	$ 66,000
Warrant [Member]
Number of warrants issued to purchase shares	284,714	3,228,572	770,987
Warrant expire date of grant	5 years	5 years
Warrant exercise price, decrease		$ 0.15
Warrant exercise price, increase		$ 0.18
22 Short-term Unsecured Loans [Member]
Proceeds from short term debt		$ 434,500
Debt instrument, interest rate, stated percentage		8.00%
Debt instrument, payment terms		Due one year from the date of issuance
Repayments of short term debt		$ 20,500
Debt instrument conversion value		$ 407,000
Debt instrument conversion shares | shares		2,800,713
Shareholder [Member]
Loans payable				$ 59,000
Loan Holders [Member] | Warrant [Member]
Number of warrants issued to purchase shares		6,038,336
Warrant expire date of grant		5 years
Warrant exercise price, decrease		$ 0.14
Warrant exercise price, increase		$ 0.18
Fair value of the warrants		$ 689,934
Fair value of additional shares issued upon conversion of loans payable from officers and shareholders		$ 30,583
Loan Holders [Member] | Warrant [Member] | Stock Price [Member] | Minimum [Member]
Stock prices		$ 0.13
Loan Holders [Member] | Warrant [Member] | Stock Price [Member] | Maximum [Member]
Stock prices		$ 0.14
Loan Holders [Member] | Warrant [Member] | Volatility [Member] | Minimum [Member]
Warrants and rights outstanding, measurement input, percent		124.60
Loan Holders [Member] | Warrant [Member] | Volatility [Member] | Maximum [Member]
Warrants and rights outstanding, measurement input, percent		124.73
Loan Holders [Member] | Warrant [Member] | Risk-free Rates [Member] | Minimum [Member]
Warrants and rights outstanding, measurement input, percent		2.37
Loan Holders [Member] | Warrant [Member] | Risk-free Rates [Member] | Maximum [Member]
Warrants and rights outstanding, measurement input, percent		2.43
Officers and Shareholders [Member]
Number of warrants issued to purchase shares		6,038,336
Warrant exercise price, decrease		$ 0.14
Warrant exercise price, increase		$ 0.18
Officers and Shareholders [Member] | Unsecured Loans [Member]
Proceeds from short term debt	$ 358,250
Debt instrument, interest rate, stated percentage	8.00%
Debt instrument, payment terms	Due one year from the date of issuance
Repayments of short term debt	$ 25,000

Convertible Note Agreements - S

Convertible Note Agreements - Schedule of Convertible Notes Payable (Details) - USD ($)		Sep. 30, 2019	Sep. 30, 2018
Debt discount - unamortized balance			$ (72,078)
Convertible notes payable, net			202,922
Convertible Note Payable One [Member]
Convertible note payable	[1]		165,000
Convertible Note Payable Two [Member]
Convertible note payable	[2]		$ 110,000
[1]	On March 5, 2018, the Company entered into a Convertible Note Payable Agreement with an individual under which the Company borrowed $165,000. Net proceeds received by the Company under the agreement after payment of a $15,000 fee to the lender was $150,000. In connection with the agreement, the Company issued the individual 300,000 restricted shares of its common stock with a fair value of $48,000 and warrants to purchase 660,000 shares of its common stock, which vested upon grant. The warrants expire five years from the date of grant and have an exercise price of $0.20 per share. The note payable accrues interest at eight percent per annum, is unsecured and is convertible at any time after the 90th day from the issue date into the Company's common stock at the fixed conversion price of $0.10 per share. The note matured in October 2018. The Company calculated the related fair value of the warrants issued to the noteholder to be $55,032 using a Black Scholes Merton option pricing model and performing a relative value calculation. The Company then made a calculation to determine if a beneficial conversion feature (BCF) existed. The beneficial conversion was based upon the effective conversion price based on the proceeds received that were allocated to the convertible instrument. Based upon the Company's calculation, it was determined that a beneficial conversion feature existed amounting to $94,968 and was recorded as a debt discount. As such the Company recognized a debt discount at the date of issuance in the aggregate amount of $165,000 relating to the $15,000 fees paid to the lender, the relative value of the warrants and the BCF. The note discount is being amortized over the term of the note and the unamortized portion is recognized as a reduction to the carrying amount of the Convertible note (a valuation debt discount). The balance of the unamortized discount at September 30, 2018 was $3,837. During the year ended September 30, 2019, the Company amended the terms of the agreement by extending the maturity date to January 2019 and reducing the conversion price from $0.10 per share to $0.07 per share. The reduction of the conversion price caused the Company to issue an additional 744,732 shares, which on the dates of amendment had a combined total fair value of $51,434, which was recorded a financing cost during the year ended September 30, 2019. During the year ended September 30, 2019, the individual converted $165,000 of the convertible note payable and $8,783 of accrued interest into 2,482,441 shares of the Company's common stock. During the year ended September 30, 2019, the Company amortized the remaining $3,837 of debt discount, leaving no unamortized balance at September 30, 2019. No amounts were outstanding under the agreement as of September 30, 2019.
[2]	On July 11, 2018, the Company entered into another Convertible Note Payable Agreement with the same individual under which the Company borrowed an additional $110,000. Net proceeds received by the Company under the agreement after payment of a $10,000 fee to the lender was $100,000. In connection with the agreement, the Company issued the individual 200,000 restricted shares of its common stock with a fair value of $36,000 and warrants to purchase 440,000 shares of its common stock, which vested upon grant. The warrants expire five years from the date of grant and have an exercise price of $0.18 per share. The note payable accrues interest at eight percent per annum, is unsecured and is convertible at any time after the 90th day from the issue date into the Company's common stock at the fixed conversion price of $0.15 per share. The note matures in February 2019, but may be extended at the option of the individual. The Company may prepay the note at any time immediately following the issue date upon seven days' prior written notice. The note was converted into shares of the Company's common stock (see below). The Company calculated the related fair value of the warrants issued to the noteholder to be $66,440 using a Black Scholes Merton option pricing model and performing a relative value calculation. The Company then made a calculation to determine if a beneficial conversion feature (BCF) existed. The beneficial conversion was based upon the effective conversion price based on the proceeds received that were allocated to the convertible instrument. Based upon the Companys calculation, it was determined that a beneficial conversion feature existed amounting to $33,560 and was recorded as a debt discount. As such the Company recognized a debt discount at the date of issuance in the aggregate amount of $110,000 relating to the $10,000 fees paid to the lender, the relative value of the warrants and the BCF. The note discount is being amortized over the term of the note and the unamortized portion is recognized as a reduction to the carrying amount of the Convertible note (a valuation debt discount). As of September 30, 2018, the Company had amortized $41,759 of debt discount, leaving an unamortized balance of $68,241 at September 30, 2018. During the year ended September 30, 2019, the Company amended the terms of the agreement by reducing the conversion price from $0.15 per share to $0.05 per share. The reduction of the conversion price caused the Company to issue an additional 1,551,854 shares, which on the date of amendment had a fair value of $108,630, which was recorded a financing cost during the year ended September 30, 2019. During the year ended September 30, 2019, the Company amortized $68,241 of debt discount, leaving no unamortized balance at September 30, 2019. On April 2, 2019, the individual converted the note payable of $110,000 and $6,389 of accrued interest into 2,327,781 shares of the Company's common stock. No amounts were outstanding under the agreement as of September 30, 2019.

Convertible Note Agreements -_2

Convertible Note Agreements - Schedule of Convertible Notes Payable (Details) (Parenthetical) - USD ($)	Apr. 02, 2019	Sep. 30, 2018	Jul. 11, 2018	Mar. 05, 2018	Sep. 30, 2019	Sep. 30, 2018
Proceeds from convertible notes payable						$ 250,000
Number of warrants issued to purchase shares					284,714
Warrant exercise price					$ 0.15
Debt instrument, unamortized discount		$ 72,078				72,078
Amortization of debt discount					$ 72,078	318,038
Convertible Note Payable Agreement One [Member]
Debt instrument, unamortized discount		3,837				3,837
Convertible Note Payable Agreement One [Member] | Individual [Member]
Debt instrument, face amount				$ 165,000
Lender fee				15,000
Proceeds from convertible notes payable				$ 150,000
Number of restricted shares issued				300,000
Restricted shares of common stock at fair value				$ 48,000
Number of warrants issued to purchase shares				660,000
Warrant term				5 years
Warrant exercise price				$ 0.20
Debt instrument, collateral				unsecured
Debt instrument, convertible, terms of conversion feature				The note payable accrues interest at eight percent per annum, is unsecured and is convertible at any time after the 90th day from the issue date into the Company's common stock at the fixed conversion price of $0.10 per share.
Debt instrument conversion price				$ 0.10
Debt instrument maturity date description				October 2018	January 2019
Fair value of warrants				$ 55,032
Debt instrument beneficial conversion feature				$ 94,968
Debt instrument, unamortized discount
Conversion of stock, shares converted					744,732
Financing cost					$ 51,434
Conversion of debt into common stock					165,000
Accrued interest					$ 8,783
Conversion of debt into common stock, shares					2,482,441
Amortization of debt discount					$ 3,837
Convertible notes payable
Convertible Note Payable Agreement One [Member] | Individual [Member] | Maximum [Member]
Debt instrument conversion price					$ 0.10
Convertible Note Payable Agreement One [Member] | Individual [Member] | Minimum [Member]
Debt instrument conversion price					$ 0.07
Convertible Note Payable Agreement Two [Member]
Financing cost					$ 108,630
Convertible Note Payable Agreement Two [Member] | Individual [Member]
Debt instrument, face amount			$ 110,000
Lender fee			10,000
Proceeds from convertible notes payable			$ 100,000
Number of restricted shares issued			200,000
Restricted shares of common stock at fair value			$ 36,000
Number of warrants issued to purchase shares			440,000
Warrant term			5 years
Warrant exercise price			$ 0.18
Debt instrument, collateral			unsecured
Debt instrument, convertible, terms of conversion feature			The note payable accrues interest at eight percent per annum, is unsecured and is convertible at any time after the 90th day from the issue date into the Company's common stock at the fixed conversion price of $0.15 per share.
Debt instrument conversion price			$ 0.15
Debt instrument maturity date description			February 2019
Fair value of warrants			$ 66,440
Debt instrument beneficial conversion feature			$ 33,560
Debt instrument, unamortized discount		68,241				$ 68,241
Conversion of stock, shares converted					1,551,854
Conversion of debt into common stock	$ 110,000
Accrued interest	$ 6,389
Conversion of debt into common stock, shares	2,327,781
Amortization of debt discount		$ 41,759			$ 68,241
Convertible notes payable
Convertible Note Payable Agreement Two [Member] | Individual [Member] | Maximum [Member]
Debt instrument conversion price		$ 0.15				$ 0.15
Convertible Note Payable Agreement Two [Member] | Individual [Member] | Minimum [Member]
Debt instrument conversion price		$ 0.05				$ 0.05

Shareholders' Equity (Details N

Shareholders' Equity (Details Narrative)	May 15, 2018$ / sharesshares	Jan. 02, 2018shares	Jan. 02, 2018shares	Nov. 30, 2018USD ($)$ / sharesshares	Sep. 30, 2019USD ($)$ / sharesshares	Sep. 30, 2018USD ($)$ / sharesshares	Sep. 30, 2017USD ($)$ / sharesshares	Jun. 30, 2010shares
Common stock, shares authorized					200,000,000	200,000,000	185,000,000
Common stock, par value | $ / shares					$ 0.001	$ 0.001	$ 0.001
Common stock, shares issued					107,497,077	100,952,569	90,284,916
Common stock, shares outstanding					107,497,077	100,952,569	90,284,916
Common stock issued for cash | $					$ 10,000	$ 177,000
Number of warrants issued to purchase common shares					284,714
Warrant exercise price | $ / shares					$ 0.15
Number of stock issued for service, amount | $					$ 79,029	$ 111,300
Number of warrants cancel					646,429
Number options to purchase of common stock		675,000			250,000	11,317,500
Options exercisable term			5 years		2 years 9 months 14 days	2 years 10 months 14 days
Options Vesting description		A combined total of 675,000 shares vested in equal amounts over a three-month period, starting on January 1, 2018, with the remainder vesting in equal amounts over the following one year and two months.
Stock based compensation | $					$ 10,366
Unvested compensation | $					330,333
Aggregate intrinsic value for warrant shares outstanding | $
Convertible Note Payable [Member]
Number of warrants issued to purchase common shares						1,100,000
Warrant term						5 years
Warrant exercise price | $ / shares						$ 0.20
Officers, Directors and Corporate Employees [Member]
Number options to purchase of common stock						8,517,500
Fair value of stock options | $						$ 1,004,450
Options exercisable term						5 years
Stock based compensation | $					$ 256,650	$ 340,699
Employee [Member]
Number options to purchase of common stock					250,000
Fair value of stock options | $					$ 10,366
Options exercisable term					5 years
Stock based compensation | $					$ 10,366
Unvested compensation | $
Officers and Shareholders [Member]
Number of warrants issued to purchase common shares						6,038,336
Warrant exercise price, decrease | $ / shares						$ 0.14
Warrant exercise price, increase | $ / shares						$ 0.18
2010 Non-Qualified Stock Option Plan [Member]
Common stock, shares authorized		30,000,000	30,000,000					7,500,000
Common Stock [Member]
Common stock issued for cash | $					$ 143	$ 1,614
Common stock issued for cash, shares					142,857	1,614,286
Number of stock issued for service					1,277,143	770,000
Number of stock issued for service, amount | $					$ 1,277	$ 770
Number of common stock for sale				296,534
Fair value of warrants | $				$ 38,935
Warrant [Member]
Number of warrants issued to purchase common shares				770,987	284,714	3,228,572
Warrant term					5 years	5 years
Warrant exercise price, decrease | $ / shares						$ 0.15
Warrant exercise price, increase | $ / shares						$ 0.18
Warrant exercise price | $ / shares				$ 0.18	$ 0.15
Number of warrants cancel						(1,600,000)
Options exercisable term					1 year 9 months 14 days
Aggregate intrinsic value for warrant shares outstanding | $
Stock Option [Member] | 2010 Non-Qualified Stock Option Plan [Member]
Shares of stock options remaining available for issuance					14,762,262
Sale of Equity Units [Member]
Number of warrants issued to purchase common shares						3,228,572
Warrant term						5 years
Warrant exercise price, decrease | $ / shares						$ 0.15
Warrant exercise price, increase | $ / shares						$ 0.18
Stock Warrants [Member]
Number of warrants cancel						1,600,000
Number of warrants exercised to purchase common stock						1,407,619
Warrants to purchase shares of common stock, value | $						$ 170,914
Minimum [Member] | Employee [Member]
Stock option exercise price per share | $ / shares					$ 0.03
Maximum [Member]
Number options to purchase of common stock			275,000
Maximum [Member] | Employee [Member]
Stock option exercise price per share | $ / shares					0.06
Equity Agreement [Member]
Warrant exercise price | $ / shares						$ 0.40
Equity Agreement [Member] | Common Stock [Member]
Number of common stock for sale						333,333	1,600,000
Purchase consideration for sales | $							$ 400,000
Sales of price per shares | $ / shares						$ 0.15
Equity Agreement [Member] | Warrant [Member]
Number of warrants issued to purchase common shares						666,667	1,600,000
Warrant exercise price | $ / shares						$ 0.18	$ 0.40
Incremental difference for warrant shares						433,000
Fair value of canceled warrants | $						$ 185,000
Fair value of warrants | $						618,000
Subscription Agreement [Member]
Sales of price per shares | $ / shares							$ 0.25
Percentage of discount for stock and warrant market price							0.40
Subscription Agreement [Member] | Common Stock [Member]
Number of common stock for sale	1,066,667
Subscription Agreement [Member] | Warrant [Member]
Number of warrants issued to purchase common shares	5,334,334
Warrant exercise price | $ / shares	$ 0.18
Subscription Agreement [Member] | Warrant [Member] | Previously [Member]
Number of warrants cancel	1,600,000
Settlement Agreement [Member]
Issuance of shares and warrants, financing cost | $						$ 56,727
Employment Agreement with Four Employees [Member]
Number options to purchase of common stock						2,800,000
Fair value of stock options | $						$ 396,308
Stock option exercise price per share | $ / shares					$ 0.14
Options exercisable term						5 years
Vesting period						3 months
Unvested compensation | $
Employment Agreement with Four Employees [Member] | Stock Option [Member]
Stock based compensation | $					$ 44,275	$ 271,804
Employment Agreement with Four Employees [Member] | Minimum [Member]
Stock option exercise price per share | $ / shares						$ 0.10
Employment Agreement with Four Employees [Member] | Maximum [Member]
Stock option exercise price per share | $ / shares						$ 0.19
Initial Equity Agreement [Member]
Number of warrants issued to purchase common shares						6,104,322
Warrant exercise price | $ / shares						$ 0.18

Shareholders' Equity - Schedule

Shareholders' Equity - Schedule of Assumptions Used for Options Granted (Details) - $ / shares	12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Expected dividends
Expected life of options	2 years 6 months	2 years 6 months
Minimum [Member]
Exercise price	$ 0.03	$ 0.10
Expected volatility	126.80%	121.10%
Risk free interest rate	1.60%	2.01%
Maximum [Member]
Exercise price	$ 0.06	$ 0.19
Expected volatility	144.00%	130.20%
Risk free interest rate	2.47%	2.85%

Shareholders' Equity - Schedu_2

Shareholders' Equity - Schedule of Stock Option Activity (Details) - USD ($)	Jan. 02, 2018	Jan. 02, 2018	Sep. 30, 2019	Sep. 30, 2018
Number of Option Shares Outstanding, Number, Beginning Balance			17,946,667	6,822,500
Number of Option Shares Outstanding, Granted	675,000		250,000	11,317,500
Number of Option Shares Outstanding, Cancelled			(646,429)	(183,333)
Number of Option Shares Outstanding, Exercised
Number of Option Shares Outstanding, Expired			(2,312,500)	(10,000)
Number of Option Shares Outstanding, Number, Ending Balance			15,237,738	17,946,667
Number of Option Shares Outstanding, Vested and exercisable, Ending Balance			12,012,738
Number of Option Shares Outstanding, Unvested, Ending Balance			3,225,000
Weighted Average Exercise Price, Number, Beginning Balance			$ 0.28	$ 0.51
Weighted Average Exercise Price, Granted			0.05	0.14
Weighted Average Exercise Price, Cancelled			0.17	0.14
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Expired			0.37	0.75
Weighted Average Exercise Price, Number, Ending Balance			0.27	$ 0.28
Weighted Average Exercise Price, Vested and exercisable, Ending Balance			0.30
Weighted Average Exercise Price, Unvested, Ending Balance			$ 0.14
Fair Value at Date of Grant, Number, Beginning Balance			$ 3,244,755	$ 1,865,628
Fair Value at Date of Grant, Granted			10,366	1,379,127
Fair Value at Date of Grant, Cancelled
Fair Value at Date of Grant, Exercised
Fair Value at Date of Grant, Expired
Fair Value at Date of Grant, Number, Ending Balance			3,255,121	$ 3,244,755
Fair Value at Date of Grant, Vested and exercisable, Ending Balance			2,803,621
Fair Value at Date of Grant, Unvested, Ending Balance			$ 451,500
Minimum [Member]
Weighted Average Exercise Price, Number, Beginning Balance			$ 0.10	$ 0.10
Weighted Average Exercise Price, Granted			0.03	0.10
Weighted Average Exercise Price, Cancelled			0.14
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Expired			0.13
Weighted Average Exercise Price, Number, Ending Balance			0.03	0.10
Weighted Average Exercise Price, Vested and exercisable, Ending Balance			0.03
Maximum [Member]
Number of Option Shares Outstanding, Granted		275,000
Weighted Average Exercise Price, Number, Beginning Balance			2	2
Weighted Average Exercise Price, Granted			0.06	0.19
Weighted Average Exercise Price, Cancelled			0.19
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Expired			0.40
Weighted Average Exercise Price, Number, Ending Balance			2	$ 2
Weighted Average Exercise Price, Vested and exercisable, Ending Balance			$ 2

Shareholders' Equity - Schedu_3

Shareholders' Equity - Schedule of Outstanding and Exercisable Options by Exercise Price Range (Details) - $ / shares	Jan. 02, 2018	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2017
Range of Exercise Prices, Lower Limit		$ 0.01
Range of Exercise Prices, Upper Limit		$ 2
Number of Options, Outstanding, Number		15,237,738	17,946,667	6,822,500
Number of Options, Outstanding, Weighted Average Remaining Contractual Term		2 years 11 months 8 days
Number of Options, Outstanding, Weighted Average Exercise Price		$ 0.27	$ 0.28	$ 0.51
Number of Options, Exercisable, Number		12,012,738
Number of Options, Exercisable, Weighted Average Remaining Contractual Term	5 years	2 years 9 months 14 days	2 years 10 months 14 days
Number of Options, Exercisable, Weighted Average Exercise Price		$ 0.30
Exercise Price Range One [Member]
Range of Exercise Prices, Lower Limit		0.01
Range of Exercise Prices, Upper Limit		$ 0.39
Number of Options, Outstanding, Number		13,775,238
Number of Options, Outstanding, Weighted Average Remaining Contractual Term		3 years 1 month 9 days
Number of Options, Outstanding, Weighted Average Exercise Price		$ 0.15
Number of Options, Exercisable, Number		10,300,238
Number of Options, Exercisable, Weighted Average Remaining Contractual Term		3 years 26 days
Number of Options, Exercisable, Weighted Average Exercise Price		$ 0.15
Exercise Price Range Two [Member]
Range of Exercise Prices, Lower Limit		0.40
Range of Exercise Prices, Upper Limit		$ 0.99
Number of Options, Outstanding, Number		62,500
Number of Options, Outstanding, Weighted Average Remaining Contractual Term		2 years 6 months
Number of Options, Outstanding, Weighted Average Exercise Price		$ 0.40
Number of Options, Exercisable, Number		312,500
Number of Options, Exercisable, Weighted Average Remaining Contractual Term		6 months
Number of Options, Exercisable, Weighted Average Exercise Price		$ 0.08
Exercise Price Range Three [Member]
Range of Exercise Prices, Lower Limit		1
Range of Exercise Prices, Upper Limit		$ 1.99
Number of Options, Outstanding, Number		750,000
Number of Options, Outstanding, Weighted Average Remaining Contractual Term		1 year 2 months 30 days
Number of Options, Outstanding, Weighted Average Exercise Price		$ 1
Number of Options, Exercisable, Number		750,000
Number of Options, Exercisable, Weighted Average Remaining Contractual Term		1 year 2 months 30 days
Number of Options, Exercisable, Weighted Average Exercise Price		$ 1
Exercise Price Range Four [Member]
Range of Exercise Prices, Upper Limit		$ 2
Number of Options, Outstanding, Number		650,000
Number of Options, Outstanding, Weighted Average Remaining Contractual Term		1 year 2 months 30 days
Number of Options, Outstanding, Weighted Average Exercise Price		$ 2
Number of Options, Exercisable, Number		650,000
Number of Options, Exercisable, Weighted Average Remaining Contractual Term		1 year 2 months 30 days
Number of Options, Exercisable, Weighted Average Exercise Price		$ 2

Shareholders' Equity - Schedu_4

Shareholders' Equity - Schedule of Warrant Activity (Details) - USD ($)	12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Number of Warrant Shares Outstanding, Cancelled	646,429
Warrant [Member]
Number of Warrant Shares Outstanding, Number, Beginning Balance	67,907,728	64,161,304
Number of Warrant Shares Outstanding, Granted	284,714	16,471,230
Number of Warrant Shares Outstanding, Cancelled		(1,600,000)
Number of Warrant Shares Outstanding, Exercised		(1,407,619)
Number of Warrant Shares Outstanding, Expired	(1,708,393)	(9,717,187)
Number of Warrant Shares Outstanding, Number, Ending Balance	66,484,049	67,907,728
Number of Warrant Shares Outstanding, Vested and exercisable, Ending Balance	66,484,049
Weighted Average Exercise Price, Number, Beginning Balance	$ 0.17	$ 0.24
Weighted Average Exercise Price, Granted	0.15	0.17
Weighted Average Exercise Price, Cancelled		0.40
Weighted Average Exercise Price, Exercised		0.12
Weighted Average Exercise Price, Expired	0.44	0.56
Weighted Average Exercise Price, Number, Ending Balance	0.17	$ 0.17
Weighted Average Exercise Price, Vested and exercisable, Ending Balance	$ 0.17
Fair Value at Date of Issuance, Beginning Balance	$ 3,434,560	$ 2,151,219
Fair Value at Date of Issuance, Granted		1,283,341
Fair Value at Date of Issuance, Cancelled
Fair Value at Date of Issuance, Exercised
Fair Value at Date of Issuance, Expired
Fair Value at Date of Issuance, Number, Ending Balance	3,434,560	$ 3,434,560
Fair Value at Date of Issuance, Vested and exercisable, Ending Balance	$ 3,434,560
Warrant [Member] | Minimum [Member]
Weighted Average Exercise Price, Number, Beginning Balance	$ 0.12	$ 0.12
Weighted Average Exercise Price, Granted		0.14
Weighted Average Exercise Price, Exercised		0.12
Weighted Average Exercise Price, Expired	0.30	0.30
Weighted Average Exercise Price, Number, Ending Balance	0.12	0.12
Weighted Average Exercise Price, Vested and exercisable, Ending Balance	0.12
Warrant [Member] | Maximum [Member]
Weighted Average Exercise Price, Number, Beginning Balance	1	1
Weighted Average Exercise Price, Granted		0.20
Weighted Average Exercise Price, Exercised		0.15
Weighted Average Exercise Price, Expired	0.67	2.31
Weighted Average Exercise Price, Number, Ending Balance	1	$ 1
Weighted Average Exercise Price, Vested and exercisable, Ending Balance	$ 1

Shareholders' Equity - Schedu_5

Shareholders' Equity - Schedule of Outstanding and Exercisable Warrants by Exercise Price Range (Details) - $ / shares	Jan. 02, 2018	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2017
Range of Exercise Prices, Lower Limit		$ 0.01
Range of Exercise Prices, Upper Limit		$ 2
Number of Warrants, Outstanding, Number		15,237,738	17,946,667	6,822,500
Number of Warrants, Outstanding, Weighted Average Remaining Contractual Term		2 years 11 months 8 days
Number of Warrants, Outstanding, Weighted Average Exercise Price		$ 0.27	$ 0.28	$ 0.51
Number of Warrants, Exercisable, Number		12,012,738
Number of Warrants, Exercisable, Weighted Average Remaining Contractual Term	5 years	2 years 9 months 14 days	2 years 10 months 14 days
Number of Warrants, Exercisable, Weighted Average Exercise Price		$ 0.30
Exercise Price Range One [Member]
Range of Exercise Prices, Lower Limit		0.01
Range of Exercise Prices, Upper Limit		$ 0.39
Number of Warrants, Outstanding, Number		13,775,238
Number of Warrants, Outstanding, Weighted Average Remaining Contractual Term		3 years 1 month 9 days
Number of Warrants, Outstanding, Weighted Average Exercise Price		$ 0.15
Number of Warrants, Exercisable, Number		10,300,238
Number of Warrants, Exercisable, Weighted Average Remaining Contractual Term		3 years 26 days
Number of Warrants, Exercisable, Weighted Average Exercise Price		$ 0.15
Exercise Price Range Two [Member]
Range of Exercise Prices, Lower Limit		0.40
Range of Exercise Prices, Upper Limit		$ 0.99
Number of Warrants, Outstanding, Number		62,500
Number of Warrants, Outstanding, Weighted Average Remaining Contractual Term		2 years 6 months
Number of Warrants, Outstanding, Weighted Average Exercise Price		$ 0.40
Number of Warrants, Exercisable, Number		312,500
Number of Warrants, Exercisable, Weighted Average Remaining Contractual Term		6 months
Number of Warrants, Exercisable, Weighted Average Exercise Price		$ 0.08
Warrant [Member]
Range of Exercise Prices, Lower Limit		0.12
Range of Exercise Prices, Upper Limit		$ 0.40
Number of Warrants, Outstanding, Number		66,484,049
Number of Warrants, Outstanding, Weighted Average Remaining Contractual Term		1 year 9 months 14 days
Number of Warrants, Outstanding, Weighted Average Exercise Price		$ 0.17
Number of Warrants, Exercisable, Number		66,484,049
Number of Warrants, Exercisable, Weighted Average Remaining Contractual Term		1 year 9 months 14 days
Number of Warrants, Exercisable, Weighted Average Exercise Price		$ 0.17
Warrant [Member] | Exercise Price Range One [Member]
Range of Exercise Prices, Lower Limit		0.12
Range of Exercise Prices, Upper Limit		$ 0.20
Number of Warrants, Outstanding, Number		59,279,384
Number of Warrants, Outstanding, Weighted Average Remaining Contractual Term		1 year 10 months 25 days
Number of Warrants, Outstanding, Weighted Average Exercise Price		$ 0.15
Number of Warrants, Exercisable, Number		59,279,384
Number of Warrants, Exercisable, Weighted Average Remaining Contractual Term		1 year 10 months 25 days
Number of Warrants, Exercisable, Weighted Average Exercise Price		$ 0.15
Warrant [Member] | Exercise Price Range Two [Member]
Range of Exercise Prices, Lower Limit		0.21
Range of Exercise Prices, Upper Limit		$ 0.40
Number of Warrants, Outstanding, Number		7,204,665
Number of Warrants, Outstanding, Weighted Average Remaining Contractual Term		10 months 6 days
Number of Warrants, Outstanding, Weighted Average Exercise Price		$ 0.26
Number of Warrants, Exercisable, Number		7,204,665
Number of Warrants, Exercisable, Weighted Average Remaining Contractual Term		10 months 6 days
Number of Warrants, Exercisable, Weighted Average Exercise Price		$ 0.26

Segment Reporting - Schedule of

Segment Reporting - Schedule of Assets of Reportable Segments (Details) - USD ($)	Sep. 30, 2019	Sep. 30, 2018
Cash	$ 53,147	$ 4,210
Prepaid expenses and other current assets	55,000	1,550
Total current assets	108,147	5,760
Property and equipment, net	1,562	2,619
Total other assets	1,562	19,379
TOTAL ASSETS	109,709	$ 25,139
Corporate [Member]
Cash	50,892
Prepaid expenses and other current assets
Total current assets	50,892
Property and equipment, net
Total other assets
TOTAL ASSETS	50,892
Medical Devices [Member]
Cash	846
Prepaid expenses and other current assets	55,000
Total current assets	55,846
Property and equipment, net
Total other assets
TOTAL ASSETS	55,846
Authentication and Encryption [Member]
Cash	1,409
Prepaid expenses and other current assets
Total current assets	1,409
Property and equipment, net	1,562
Total other assets	1,562
TOTAL ASSETS	$ 2,971

Segment Reporting - Schedule _2

Segment Reporting - Schedule of Operations of Reportable Segments (Details) - USD ($)	9 Months Ended	12 Months Ended
	Jun. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Total Sales	$ 213,723	$ 33,375	$ 213,723
Cost of goods sold	79,960	20,025	79,960
Gross profit	133,763	13,350	133,763
Operating expenses	2,226,362	1,779,934	2,226,362
Loss from operations	(2,092,599)	(1,766,584)	(2,092,599)
Trade [Member]
Total Sales	140,023	19,508	140,023
Consulting Services [Member]
Total Sales	73,700	13,867	$ 73,700
Corporate [Member]
Total Sales
Cost of goods sold
Gross profit
Operating expenses	1,179,937	782,961
Loss from operations	(1,179,937)	(782,961)
Corporate [Member] | Trade [Member]
Total Sales
Corporate [Member] | Consulting Services [Member]
Total Sales
Medical Devices [Member]
Total Sales	45,000
Cost of goods sold
Gross profit	45,000
Operating expenses	224,196	641,236
Loss from operations	(179,196)	(641,236)
Medical Devices [Member] | Trade [Member]
Total Sales	45,000
Medical Devices [Member] | Consulting Services [Member]
Total Sales
Authentication and Encryption [Member]
Total Sales	168,723	33,375
Cost of goods sold	79,960	20,025
Gross profit	88,763	13,350
Operating expenses	822,229	355,737
Loss from operations	(733,466)	(342,387)
Authentication and Encryption [Member] | Trade [Member]
Total Sales	95,023	19,508
Authentication and Encryption [Member] | Consulting Services [Member]
Total Sales	$ 73,700	$ 13,867

Legal Matters (Details Narrativ

Legal Matters (Details Narrative)	12 Months Ended
	Sep. 30, 2019USD ($)
Payment to negotiated settlement	$ 89,302
Interest rate of negotiated settlement	4.00%
Wages	$ 21,600
Wages increase rate	2.00%
CEO [Member] | Minimum [Member]
Trading expense	$ 130,000

Commitments (Details Narrative)

Commitments (Details Narrative) - USD ($)	Oct. 02, 2016	Sep. 30, 2019	Sep. 30, 2018	Jan. 06, 2020
Lease expiration date		Feb. 28, 2024
Monthly lease payment		$ 11,000
Lease obligation remaining		631,587
Security deposit relating to the lease		15,000
Rent Expenses		$ 180,946	$ 188,801
Base salary			$ 350,000
StealthCo [Member] | Ownership Agreement [Member] | Subsequent Event [Member]
Non-cancellable lease payment				$ 11,000
StealthCo [Member] | Non Cancellable Lease Agreement [Member]
Lease expiration date	Sep. 30, 2021
Lease term	5 years

Commitments - Summary of Minimu

Commitments - Summary of Minimum Annual Rental Commitments Under Non-cancelable Leases (Details)	Sep. 30, 2019USD ($)
Commitments and Contingencies Disclosure [Abstract]
2020	$ 21,600
2021	7,200
TOTAL	$ 28,800

Income Taxes (Details Narrative

Income Taxes (Details Narrative)	12 Months Ended
	Sep. 30, 2019USD ($)
Income Tax Disclosure [Abstract]
Net operating loss carryforwards for federal income tax	$ 18,000,000
Net operating loss carryforwards expire year	Future taxable income through 2038.
Deferred tax carryforwards offset by valuation allowance	$ 4,000,000

Income Taxes - Schedule of Effe

Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)	12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Income Tax Disclosure [Abstract]
Income tax benefit at federal statutory rate	(21.00%)	(21.00%)
State income tax benefit, net of federal benefit	(4.00%)	(4.00%)
Change in valuation allowance	25.00%	25.00%
Income taxes at effective income tax rate

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)	Sep. 30, 2019	Sep. 30, 2018
Income Tax Disclosure [Abstract]
Net operating loss carryforwards	$ 4,657,556	$ 4,307,629
Less: Valuation allowance	(4,657,556)	(4,307,629)
Net deferred tax assets

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	Jan. 02, 2018	Jan. 02, 2018	Sep. 30, 2019	Sep. 30, 2018
Stock options to purchase a common stock granted	675,000		250,000	11,317,500
Stock option granted exercise price per shares			$ 0.05	$ 0.14
Options exercisable term		5 years	2 years 9 months 14 days	2 years 10 months 14 days
Lease expiration date			Feb. 28, 2024
Corporate Office Facility [Member]
Lease expiration date			Feb. 28, 2024
Andrew J. Kandalepas [Member]
Officers compensation			$ 133,333	$ 182,375
Stock options to purchase a common stock granted				1,300,000
Stock option granted exercise price per shares				$ 0.14
Options exercisable term				5 years
Accrued compensation			$ 33,964	$ 81,965

Proposed Sale of Stealthco, I_2

Proposed Sale of Stealthco, Inc. (Details Narrative) - USD ($)	Dec. 31, 2021	Sep. 03, 2019	Sep. 30, 2019	Sep. 30, 2018
Common stock new issue value			$ 10,000	$ 177,000
Share Exchange Agreement [Member] | DTI Holdings Inc [Member]
Due from related party			500,000
Due from related party in addition			$ 500,000
Agreement description		On September 3, 2019, the Company's Board of Directors unanimously approved, subject to stockholder approval: (1) execution and delivery of a proposed Share Exchange Agreement with DTI Holdings, Inc. ("DTI") relating to the share exchange and transfer of certain assets of StealthCo, Inc. ("SCI") pursuant to the terms and conditions of a Memorandum of Agreement in substantially the form of the copy presented to the Board ("Agreement"). As of September 18, 2019, holders of a majority of the outstanding shares of voting capital stock have executed written stockholder consents approving this action. The Agreement provides, among other things, that: (1) DTI will pay the Company $500,000 upon the execution of a definitive share exchange agreement ("Share Exchange Agreement") which the parties will endeavor to negotiate and execute as quickly as possible, and not later than October 15, 2019; (2) DTI will pay the Company an additional $500,000 within seven days following the completion date of the transfer of all assets and/or full ownership of SCI to DTI, with such date to occur within 120 days following execution of the Share Exchange Agreement; (3) DTI will issue to the Company 3,112,000 shares of DTI common stock and will guaranty that the value of the 3,112,000 shares of DTI common stock will have a value of at least $4.50 per share ($14,004,000, in the aggregate), as of December 31, 2021; (4) To the extent that the value of the DTI common shares, as of December 31, 2021, is less than $4.50 per share ($14,004,000, in the aggregate), DTI will issue additional shares of DTI common stock, at the then current fair market value, in an amount sufficient to cause the resulting aggregate value of all shares of DTI common stock issued to the Company to be $14,004,000, in the aggregate; (5) DTI will assign the assets transferred by SCI, including trademarks, intellectual properties, and patents, to its subsidiary, Femtobitz, Inc., a Delaware corporation, and will pay to the Company 1% of annual gross revenue arising from or relating to operation of Femtobitz, Inc.; and (6) Upon closing of the share exchange, the Company's Chairman will be appointed an advisory board member of DTI and a board member of Femtobitz, Inc. As of September 18, 2019, stockholders holding a majority of our outstanding common stock approved the share exchange and the Company began discussions and negotiations with DTI, which are currently on-going. There can be no assurance that the proposed transaction will be concluded successfully on the terms described or any alternate terms that may be proposed hereafter.
Share Exchange Agreement [Member] | Femtobitz, Inc. [Member]
Annual gross revenue			1.00%
Share Exchange Agreement [Member] | Forecast [Member] | DTI Holdings Inc [Member]
Common stock new issues	3,112,000
Common stock value per share	$ 4.50
Common stock new issue value	$ 14,004,000

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Mar. 31, 2020	Dec. 31, 2019	Oct. 02, 2016	Dec. 31, 2018	Jan. 24, 2020	Sep. 30, 2019	Jan. 06, 2020	Sep. 30, 2018
Loans payable from officers and shareholders						$ 399,250		$ 66,000
Contributed capital				$ 700,000
Lease expiration date						Feb. 28, 2024
Number of securities called by warrants						284,714
Exercise price of warrants						$ 0.15
StealthCo [Member] | Non Cancellable Lease Agreement [Member]
Lease expiration date			Sep. 30, 2021
Lease term			5 years
Officers and Shareholders [Member]
Number of securities called by warrants								6,038,336
Officers and Shareholders [Member] | Unsecured Loans [Member]
Debt instrument, interest rate, stated percentage						8.00%
Debt instrument, payment terms						Due one year from the date of issuance
Subsequent Event [Member]
Debt instrument, payment terms					Due one year from the date of issuance
Number of securities called by warrants		66,000,000
Incremental fair value of warrants	$ 700,000
Subsequent Event [Member] | Minimum [Member]
Exercise price of warrants		$ 0.12
Subsequent Event [Member] | Maximum [Member]
Exercise price of warrants		$ 0.40
Subsequent Event [Member] | September 30, 2020 [Member]
Number of securities called by warrants		20,000,000
Subsequent Event [Member] | September 30, 2020 [Member] | Minimum [Member]
Exercise price of warrants		$ 0.15
Subsequent Event [Member] | September 30, 2020 [Member] | Maximum [Member]
Exercise price of warrants		$ 0.25
Subsequent Event [Member] | NEO Phototherapy, LLC, [Member]
Contributed capital					$ 50,000
Subsequent Event [Member] | GEN2 Funding, Inc., [Member]
Investments to others		$ 975,000
Subsequent Event [Member] | StealthCo [Member] | Ownership Agreement [Member]
Non-cancellable lease payment							$ 11,000
Subsequent Event [Member] | Unsecured Loans [Member]
Debt instrument, interest rate, stated percentage					8.00%
Subsequent Event [Member] | Officers and Shareholders [Member]
Loans payable from officers and shareholders					$ 310,000
Subsequent Event [Member] | Board of Directors [Member]
Unexpired stock warrants, extension period		1 year